FDA Banned Supplements List 2026 + DoD Prohibited List
Not medical advice. This page reproduces public FDA and Department of Defense lists with their source links; it does not test products and does not say whether any product on Amazon contains these ingredients.
Quick answer
FDA does not publish a single “banned supplements” list. Three lists exist, and they are different things. The FDA Health Fraud Product Database names products found to contain a hidden drug: 1,406 such notifications from 2007 to 2026, 81 of them in the last 12 months. FDA’s Dietary Supplement Ingredient Directory lists 84 ingredients FDA has made a statement about, 61 of which it says cannot lawfully be in a supplement. The DoD prohibited-ingredients list applies to service members: 850 entries reachable through its search (a lower bound), last updated by OPSS on 26 May 2026.
A product can be legal for you and prohibited for a soldier; an ingredient can be on no list and still be undeclared sildenafil in a “natural” capsule. How to check a product →
On this page
List 1: ingredients FDA says cannot lawfully be in a supplement
SourceFDA, Dietary Supplement Ingredient Directory (“Information on Select Dietary Supplement Ingredients and Other Substances”), content current as of 2026-05-01, fetched 2026-09-21: 84 entries. Each entry carries FDA’s category code; codes 3 to 7 mean FDA has said the substance is not a lawful dietary ingredient, is a drug, or has not met the safety standard. Codes 1 and 2 are health-claim letters and safety communications, not bans, and are listed separately below.
| Ingredient | Other names | FDA status (category) | FDA action | Listed / updated |
|---|---|---|---|---|
| 1,4 DMAA | 1,4-dimethylamylamine; 1,4-dimethylpentylamine | 3: not a dietary ingredient (201(ff)(1)) | Safety Communication; Hi Tech Pharmaceuticals Voluntary Recall | 2023/04 |
| 5-Alpha-Hydroxy-Laxogenin | 5-laxogenin; 5a-Hydroxy-Laxogenin; (25R)-3beta,5alpha -Dihydroxyspirostan-6-one; 25-R-Spirostan-5A-Diol-6 -One-3-One | 3: not a dietary ingredient (201(ff)(1)) | Constituent update and warning letters; Advanced Nutritional Supplements LLC Warning Letter | 2023/03 |
| 7-hydroxymitragynine | 7-HMG; 7-hydroxy; 7-OH; 7-OH-MIT | 2: safety communication; 6: new dietary ingredient fails the safety standard (402(f)(1)(B)) | Hiding in Plain Sight: 7-OH Products; Press release and warning letters | 2025/12 |
| Acacia rigidula | Vachellia rigidula; Chaparro Prieto; Blackbrush | 7: new dietary ingredient with no premarket notification (413(a)(2)) | Acacia rigidula in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| Acetaminophen | Acetamide, N-(4-hydroxyphenyl)-; Paracetamol; Tylenol™ | 4: excluded from the supplement definition (201(ff)(3): a drug) | Procter and Gamble Warning Letter | 2023/04 |
| ALA Phosphate | 5-aminolevulinic acid phosphate; NatuALA | 4: excluded from the supplement definition (201(ff)(3): a drug) | Neo ALA NDIN 1094 Response Letter | 2023/06 |
| Amanita muscaria | Fly agaric; Fly amanita; ibotenic acid; muscimol | 2: safety communication; 6: new dietary ingredient fails the safety standard (402(f)(1)(B)) | Constituent Update | 2025/12 |
| Aminophylline | Aminocardol; Cardiomin; Stenovasan; Vasofilina | 4: excluded from the supplement definition (201(ff)(3): a drug) | RT Naturals, LLC Warning Letter | 2023/04 |
| Anatabine | Anatabloc | 3: not a dietary ingredient (201(ff)(1)); 4: excluded from the supplement definition (201(ff)(3): a drug) | Rock Creek Pharmaceuticals NDIN 840 Response Letter; Star Scientific, Inc. Warning Letter | 2023/04 |
| Aspirin | Acetylsalicylic acid; 2-Acetoxybenzoic acid; 2-Carboxyphenyl acetate; Kyselina 2-acetoxybenzoova | 4: excluded from the supplement definition (201(ff)(3): a drug) | Bayer HealthCare L.L.C Warning Letter | 2023/04 |
| BMPEA | R-beta-methylphenethylamine; R-beta-methylphenethylamine HCl; Beta-methylphenethylamine; 2- phenyl-1-propanamine | 3: not a dietary ingredient (201(ff)(1)) | BMPEA in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| Calcifediol | 25-hydroxycholecalciferol; 25-hydroxy vitamin D3; Calcifediol anhydrous; Dedrogyl | 4: excluded from the supplement definition (201(ff)(3): a drug) | DSM Nutritional Products NDIN 945 Response Letter | 2023/04 |
| Cannabidiol | CBD | 4: excluded from the supplement definition (201(ff)(3): a drug) | FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD); Warning Letters and Test Results for Cannabidiol-Related Products | 2023/03 |
| Cesium chloride | — | 2: safety communication; 6: new dietary ingredient fails the safety standard (402(f)(1)(B)) | Cesium Chloride in Dietary Supplements; Safety communication | 2023/03 |
| Chlorzoxazone | 2-Hydroxy-5-chlorobenzoxazole; 5-Chlorbenzoxazolin-2-on; 5-Chloro-2-benzoxazolinone; 5-Chloro-2-benzoxazolol | 4: excluded from the supplement definition (201(ff)(3): a drug) | West Coast Laboratories, Inc. Warning Letter; Human Science Foundation Warning Letter | 2023/04 |
| Cotinine HCl | Cotinine; 1-methyl-5-(3-pyridinyl)-2 -pyrrolidinone | 4: excluded from the supplement definition (201(ff)(3): a drug) | Capsulean LLC NDIN 1122 Response Letter | 2023/04 |
| Dapoxetine | Dapoxetinum | 4: excluded from the supplement definition (201(ff)(3): a drug) | Shoreside Enterprises, Inc. Warning Letter | 2023/04 |
| Diclofenac | Dichlofenac; Diclophenac; Feloran; Novapirina | 4: excluded from the supplement definition (201(ff)(3): a drug) | Naturista Store LLC Warning Letter; Safety Communication | 2026/05 |
| DMAA | 1,3-DMAA; 1,3-Dimethylamylamine; 1,3-Dimethylpentylamine; 4-Methyl-2-hexanamine | 3: not a dietary ingredient (201(ff)(1)) | DMAA in Products Marketed as Dietary Supplements | 2023/03 |
| DMBA | 1,3-Dimethylbutylamine; 4-Amino-2-Methylpentane Citrate; 4-Amino Methylpentane Citrate; Amperall | 7: new dietary ingredient with no premarket notification (413(a)(2)) | DMBA in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| DMHA | 1,5-Dimethylhexylamine; 1,5-DMHA; 2-amino-6-methylheptane; 2-aminoisoheptane | 3: not a dietary ingredient (201(ff)(1)) | DMHA in Dietary Supplements | 2023/03 |
| DMSA | 2,3-Dimercaptosuccinic acid; 2,3-Dimercaptobutanedioic acid; Succicaptal; Suximer | 4: excluded from the supplement definition (201(ff)(3): a drug) | Northern Health Products Warning Letter; Nutri-Dyn Midwest, Inc. Warning Letter | 2023/04 |
| Doxylamine | 2-Dimethylaminoethoxyphenylmethyl -2-picoline | 4: excluded from the supplement definition (201(ff)(3): a drug) | Arco Globus Trading, LLC et al. Warning Letter | 2023/04 |
| Ephedrine alkaloids | Ephedrine alkaloid sources include raw botanicals (i.e., plants) and extracts from botanicals:; Ephedra sinica Stapf; Ephedra equisetina Bunge; Ephedra intermedia var. tibetica Stapf | 5: fails the safety standard (402(f)(1)(A)) | 69 Fed. Reg. 6787 | 2023/03 |
| Galantamine | Galantamine HBr | 4: excluded from the supplement definition (201(ff)(3): a drug) | Life Enhancement Products, Inc. Warning Letter | 2024/02 |
| HCG | Human chorionic gonadotropin; APL (hormone); Biogonadil; Follutein | 4: excluded from the supplement definition (201(ff)(3): a drug) | The hCG Drops, LLC Warning Letter; Theoriginalhcgdrops.com Warning Letter | 2023/04 |
| Higenamine | Norcoclaurine; Demethylcoclaurine | 7: new dietary ingredient with no premarket notification (413(a)(2)) | Constituent update and warning letters; Ironmag Labs Warning Letter | 2023/03 |
| Higenamine HCl | Norcoclaurine HCl; Demethylcoclaurine HCl | 3: not a dietary ingredient (201(ff)(1)) | Constituent update and warning letters; Advanced Nutritional Supplements LLC Warning Letter | 2023/03 |
| Homotaurine | Acamprosate; Tramiprosate; 3-Amino-1-propanesulfonic acid; 3-Aminopropanesulphonic acid | 3: not a dietary ingredient (201(ff)(1)); 4: excluded from the supplement definition (201(ff)(3): a drug) | OVOS Natural Health, Inc. Citizen Petition Response; Chemtech Pharmics, Inc. NDIN 43 Response Letter | 2023/04 |
| Hordenine | N,N-dimethyltyramine; p-hydroxy-N,N-dimethylphenethylamine; para-hydroxy-N,N-dimethylphenethylamine; 4-hydroxy-N,N-dimethylphenethylamine | 7: new dietary ingredient with no premarket notification (413(a)(2)) | Constituent update and warning letters; Ironmag Labs Warning Letter | 2023/03 |
| Hordenine HCl | N,N-dimethyltyramine HCl; p-hydroxy-N,N-dimethylphenethylamine HCl; para-hydroxy-N,N-dimethylphenethylamine HCl; 4-hydroxy-N,N-dimethylphenethylamine HCl | 3: not a dietary ingredient (201(ff)(1)) | Constituent update and warning letters; Advanced Nutritional Supplements LLC Warning Letter | 2023/03 |
| Ibuprofen | Advil; Midol; Motrin; Nuprin | 4: excluded from the supplement definition (201(ff)(3): a drug) | West Coast Laboratories, Inc. Warning Letter; Human Science Foundation Warning Letter | 2023/04 |
| Ibutamoren | ibutamoren mesylate; MK-677; MK-0677; L-163,191 | 4: excluded from the supplement definition (201(ff)(3): a drug) | Agebox Inc. Warning Letter; Musclepower Enterprise Ltd. dba MONSTER KING and GE LABS Warning Letter | 2026/05 |
| Indomethacin | Amuno; Indocid; Indocin; Indomet 140 | 4: excluded from the supplement definition (201(ff)(3): a drug) | West Coast Laboratories, Inc. Warning Letter; Human Science Foundation Warning Letter | 2023/04 |
| Kratom | Kratom; Mitragyna speciosa | 2: safety communication; 6: new dietary ingredient fails the safety standard (402(f)(1)(B)) | FDA and Kratom; Import Alert 54-15 | 2023/03 |
| L-DOPA | Levodopa; Larodopa; L-3,4-dihydroxyphenylalanine | 4: excluded from the supplement definition (201(ff)(3): a drug) | RT Naturals, LLC Warning Letter | 2023/04 |
| LGD-4033 | VK-5211; Anabolicum; Ligandrol | 2: safety communication; 4: excluded from the supplement definition (201(ff)(3): a drug) | SARMs Safety Communication; Infantry Labs, LLC/1 Nation Nutrition Warning Letter | 2024/02 |
| Lorcaserin | Belvig; Belviq; AR-10A; APD-356 | 4: excluded from the supplement definition (201(ff)(3): a drug) | HIS Enterprise Inc dba Adam’s Secret USA, LLC Warning Letter | 2023/04 |
| Metformin | Fluamine; N,N-Dimethyldiguanide; NNDG | 4: excluded from the supplement definition (201(ff)(3): a drug) | Amrutam Life Care Pvt. Ltd. Cyber Letter | 2023/04 |
| Methylsynephrine | Oxilofrine; p-hydroxyephedrine; para-hydroxyephedrine; 4-hydroxyephendrine | 3: not a dietary ingredient (201(ff)(1)) | Methylsynephrine in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| N-acetyl-L-cysteine | NAC; N-acetylcysteine; Acetyl Cysteine; Acetylcysteine | 4: excluded from the supplement definition (201(ff)(3): a drug) | Citizen petition response; Guidance for Industry: Policy Regarding N-acetyl-L-cysteine | 2023/03 |
| N-Methyltyramine | Methyl-4-tyramine; 4-[2-(Methylamino)ethyl]phenol; p-(2-Methylaminoethyl)phenol; 4-Hydroxy-N-methylphenethylamine | 7: new dietary ingredient with no premarket notification (413(a)(2)) | Carbon Fire, LLC Warning Letter | 2024/05 |
| Naproxen | Aleve; Anaprox; Methoxypropiocin; Naprosin | 4: excluded from the supplement definition (201(ff)(3): a drug) | West Coast Laboratories, Inc. Warning Letter; Human Science Foundation Warning Letter | 2023/04 |
| Nerium oleander | Oleandrin; Corrigen; Foliandrin; Folinerin | 2: safety communication; 4: excluded from the supplement definition (201(ff)(3): a drug) | Phoenix Biotechnology, Inc. NDIN 1157 Response Letter; Ozelle Pharmaceuticals, Inc NDIN 37 Response Letter | 2023/04 |
| Octopamine | para-octopamine; p-octopamine; alpha-(Aminoethyl)-p-hydroxybenzyl alcohol; beta-hydroxytyramine | 7: new dietary ingredient with no premarket notification (413(a)(2)) | Constituent update and warning letters; Max Muscle Warning Letter | 2023/03 |
| Ostarine | Enobosarm; MK-2866; GTx-024; Ostabolic | 2: safety communication; 4: excluded from the supplement definition (201(ff)(3): a drug) | SARMs Safety Communication; Infantry Labs, LLC/1 Nation Nutrition Warning Letter | 2024/02 |
| Phenibut | fenibut; phenigam; PhGaba; PGaba | 3: not a dietary ingredient (201(ff)(1)) | Phenibut in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| Picamilon | pikatropin; pikamilon; nicotinyl-gamma-aminobutyric acid; nicotinoyl-GABA | 3: not a dietary ingredient (201(ff)(1)) | Picamilon in Dietary Supplements; Constituent update and warning letters | 2023/03 |
| Piroxicam | Feldene; Piroftal; Rosiden; Roxicam | 4: excluded from the supplement definition (201(ff)(3): a drug) | West Coast Laboratories, Inc. Warning Letter | 2023/04 |
| Procysteine | Cystox; Oxothiazolidine carboxylate, L-; Koprosteine | 4: excluded from the supplement definition (201(ff)(3): a drug) | Scientific Systems NDIN 907 Response Letter | 2023/04 |
| Pure and Highly Concentrated Caffeine | — | 2: safety communication; 5: fails the safety standard (402(f)(1)(A)) | Pure and Highly Concentrated Caffeine; Safety communication | 2023/03 |
| Pyridoxamine | Pyridoxamine hydrochloride; Pyridoxylamine | 4: excluded from the supplement definition (201(ff)(3): a drug) | Citizen petition response | 2023/03 |
| Red yeast rice | Red yeast rice is produced by fermentation of a yeast (Monascus purpureus) on rice. It is a source of monacolins, including monocolin K (also known as lovastatin, the active pharmaceutical ingredient in Mevacor).; Monacolin K; Lovastatin | 4: excluded from the supplement definition (201(ff)(3): a drug) | Safety communication; Pharmanex, Inc. v. Shalala, 221 F.3d 1151 (10th Cir. 2000) | 2023/03 |
| Sarcosine | N-methyglycine; Magnesium Sarcosylate; Sarcosine Hydrochloride; Sodium Sarcosinate | 4: excluded from the supplement definition (201(ff)(3): a drug) | Hsiu-Mei Chao NDIN 389 Response Letter | 2023/04 |
| Sibutramine | Meridia; Reductil; Didesmethylsibutramine; sibutramine hydrochloride | 4: excluded from the supplement definition (201(ff)(3): a drug) | X2 Zero Corporation Warning Letter; Shaping Beauty, Inc. Warning Letter | 2023/04 |
| Sildenafil | Acetildenafil; Desmethyl Sildenafil; Homosildenafil; Hydroxyhomosildenafil | 4: excluded from the supplement definition (201(ff)(3): a drug) | Thirsty Run LLC / US Royal Honey LLC Warning Letter; MS Bionic Warning Letter | 2023/04 |
| Sulbutiamine | sulbutiamina; sulbutiaminum; arcalion; bisibuthiamine | 3: not a dietary ingredient (201(ff)(1)) | Gluten Free Remedies LLC Warning Letter | 2025/05 |
| Tadalafil | Cialis; Adcirca | 4: excluded from the supplement definition (201(ff)(3): a drug) | 1am USA Incorporated dba Pleasure Products USA Warning Letter; MS Bionic Warning Letter | 2023/04 |
| Terazosin | Blavin; Flumarc; Fosfomic; Vasomet | 4: excluded from the supplement definition (201(ff)(3): a drug) | USA Far Ocean Group Inc./Health & Beauty Group Inc. Warning Letter | 2023/04 |
| Tianeptine | Tianeptine sulfate; Tianeptine sodium powder; Tianeptine acid | 2: safety communication; 3: not a dietary ingredient (201(ff)(1)) | Tianeptine in Dietary Supplements; Health Fraud Scams – Tianeptine | 2023/03 |
| Vardenafil | Levitra; Staxyn; Vivanza | 4: excluded from the supplement definition (201(ff)(3): a drug) | Biogenix USA, LLC Warning Letter | 2023/04 |
61 of 84 directory entries. Category counts across the directory: 1: 13 · 2: 19 · 3: 14 · 4: 37 · 5: 2 · 6: 4 · 7: 6 (an entry can carry more than one code). Category wording is FDA’s: (3) Ingredient is not a "dietary ingredient" under section 201(ff)(1) of the FD&C Act; (4) Ingredient is excluded from the dietary supplement definition under section 201(ff)(3) of the FD&C Act; (5) Dietary ingredient has not met the safety standard in section 402(f)(1)(A) of the FD&C Act; (6) New dietary ingredient has not met the safety standard in section 402(f)(1)(B) of the FD&C Act; (7) New dietary ingredient requiring a premarket safety notification under section 413(a)(2) of the FD&C Act but for which no notification has been submitted.
The other 23 directory entries: health-claim letters and safety communications (not bans)
List 2: products FDA found to contain a hidden drug
SourceFDA, Health Fraud Product Database (the successor of the “Tainted Products Marketed as Dietary Supplements” list; the old address redirects here), fetched 2026-09-21. The database holds 2,202 rows across every FDA program; we keep the 1,406 whose subject names an undeclared or hidden ingredient, and classify each by that ingredient. FDA itself warns the list “only includes a small fraction of the potentially hazardous products marketed to consumers”.
| Hidden-ingredient type (our classification) | Notifications | Typical hidden drugs |
|---|---|---|
| sexual enhancement | 802 | sildenafil, tadalafil, vardenafil and unapproved analogues (sulfoaildenafil, aminotadalafil) |
| weight loss | 428 | sibutramine, phenolphthalein, fluoxetine, lorcaserin |
| muscle building | 93 | anabolic steroids (Superdrol, Madol, Tren), SARMs, androstenedione |
| other | 136 | NSAIDs (diclofenac), corticosteroids (dexamethasone), yellow oleander, other drugs |
| Most-named hidden ingredients | Rows |
|---|---|
| sildenafil | 458 |
| sibutramine | 350 |
| tadalafil | 261 |
| phenolphthalein | 98 |
| superdrol | 89 |
| steroids | 88 |
| madol | 88 |
| androstenedione | 88 |
| turinabol | 88 |
| sulfoaildenafil | 86 |
| tren | 83 |
| diclofenac | 56 |
Notifications by year: 2007: 15 · 2008: 83 · 2009: 137 · 2010: 71 · 2011: 42 · 2012: 47 · 2013: 95 · 2014: 99 · 2015: 129 · 2016: 81 · 2017: 98 · 2018: 73 · 2019: 66 · 2020: 70 · 2021: 33 · 2022: 38 · 2023: 45 · 2024: 76 · 2025: 44 · 2026: 64. The year-to-year swings track FDA’s enforcement sweeps (import screening and online purchases), not the size of the market.
Every notification since 2025-01-01 (108 products)
| Date | Product | Hidden ingredient(s) | Type | Sold via | FDA action |
|---|---|---|---|---|---|
| 2026-09-15 | LUZE Fit | sibutramine | weight loss | shop.app | Public Notification |
| 2026-09-15 | Beauty 911 | sibutramine | weight loss | shop.app | Public Notification |
| 2026-09-15 | DEEP | amino tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-09-04 | ZUBB Dietary Supplement | sildenafil | sexual enhancement | International Mail Shipments | Public Notification |
| 2026-09-02 | MAXMAN Coffee | sildenafil, tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-08-25 | Qu Feng Huo Lou Dan | dexamethasone | other | newgreenusa.com | Public Notification |
| 2026-08-18 | Esbelta Chupapanza Flat Belly | phenolphthalein | weight loss | elegantfigure.com | Public Notification |
| 2026-08-18 | Esbelta Intense Loss | sibutramine, desmethyl sibutramine, benzyl sibutramine, sildenafil | sexual enhancement, weight loss | elegantfigure.com | Public Notification |
| 2026-08-12 | Premium OrgaZEN 10000 | sildenafil | sexual enhancement | — | Public Notification |
| 2026-08-12 | Anaconda Premium 500K | tadalafil | sexual enhancement | — | Public Notification |
| 2026-08-12 | DMagic Plus | diclofenac, neriifolin, thevetin B | other | lamilagrosalab.com | Public Notification |
| 2026-08-12 | B. MAGI | phenolphthalein, neriifolin, thevetin B | weight loss | lamilagrosalab.com | Public Notification |
| 2026-07-23 | Kangaroo Intense Venus 3000 | sildenafil | sexual enhancement | usroyalhoney.com | Public Notification |
| 2026-07-14 | Xian Ling | tapentadol, meloxicam | other | Various Distributors | Public Notification |
| 2026-07-14 | Detoxi Slim People's Bazaar II | sibutramine | weight loss | International Mail Shipments | Public Notification |
| 2026-07-01 | MAGNUM XXL 300K Honey | sildenafil, tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-06-24 | PRE-FORMANCE BLACK | 1, 4-dimethylamylamine, DMAA | weight loss | advancedsupps.com | Public Notification |
| 2026-06-10 | Branch Manager for Men | yohimbine | sexual enhancement | supplx.com | Public Notification |
| 2026-06-10 | Business Pill | yohimbine | sexual enhancement | supplx.com | Public Notification |
| 2026-06-05 | Pink Pussycat brand products | sildenafil, tadalafil | sexual enhancement | Various websites | Public Notification |
| 2026-06-04 | Lipofit Extreme 2.0 Fat Burner Ana Salazar Modela Tu Cuerpo Inc. | fluoxetine, 2, 4-dinitrophenol (DNP) | weight loss | anasalazar.us.com | Public Notification |
| 2026-06-04 | Juicy AF! | sildenafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-05-29 | Taewon Liar Bella's Nutri Shop | meloxicam, ketorolac, dexamethasone, tapentadol | other | bproductline.com; etsy.com | Public Notification |
| 2026-05-29 | Baipho Herbs Tea Drink | piroxicam | other | amazon.com | Public Notification |
| 2026-05-29 | Big Dick Energy! | tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-05-29 | X10 Natural Enhancement Supplement A&P Creations LLC | sildenafil, tadalafil | sexual enhancement | naturefuel.us | Public Notification |
| 2026-05-29 | Erectus Plus | sildenafil, tadalafil, testosterone propionate | sexual enhancement, muscle building | ebay.com | Public Notification |
| 2026-05-29 | Sensual Miracle Honey | sildenafil, tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-05-28 | Better Weather Fix Elixir 15 ml Better Weather Activities LLC | Mitragynine, Mitragynine Pseudoindoxyl (Kratom) | other | — | Recall |
| 2026-05-27 | biQ-FEL A&P Creations LLC | sildenafil, tadalafil | sexual enhancement | walmart.com; biqfelusa.com | Public Notification |
| 2026-05-15 | Sâm Xương Khớp Ông Tiên | piroxicam, dexamethasone phosphate | other | ongtienlinhchi.com | Public Notification |
| 2026-05-11 | Better Weather Fix Elixir products XD Investments LLC | Mitragynine, Mitragynine Pseudoindoxyl (Kratom) | other | — | Recall |
| 2026-05-07 | Hard AF! | sildenafil, tadalafil | sexual enhancement | Various Distributors | Public Notification |
| 2026-05-05 | RAPTURE Preworkout | 1, 3-dimethylamylamine (DMAA) | weight loss | leaderformulas.com | Public Notification |
| 2026-04-24 | New Hyaluronic Acid 850 mg Sealed 30 Caps, Umary ibeautistore.com | diclofenac, dexamethasone, omeprazole | other | ibeautistore.com | Public Notification |
| 2026-04-07 | Yeicob Ácido Hialurónico Ray's Vitamins | dexamethasone phosphate, diclofenac | other | raysvitamins.com | Public Notification |
| 2026-04-07 | KUKA FLEX CBD | diclofenac | other | ebay.com | Public Notification |
| 2026-04-07 | DINA Acido Hialurónico | dexamethasone, methocarbamol, meloxicam, phenolphthalein | weight loss | ebay.com | Public Notification |
| 2026-04-07 | RM Joe | dexamethasone phosphate, diclofenac | other | naturistamexicanstore.com | Public Notification |
| 2026-04-07 | Curcuflex | dexamethasone, diclofenac | other | ebay.com | Public Notification |
| 2026-04-07 | Umary Various | diclofenac, dexamethasone, omeprazole | other | solovital.com; Main Products, Inc.; ebay.com | Public Notification |
| 2026-04-06 | WAP Sensual Enhancement Best Supplements Best Prices | sildenafil, tadalafil, flibanserin | sexual enhancement | ebay.com | Public Notification |
| 2026-04-03 | Addall XR Shot ZMB Enterprises, LLC | 2-amino-6-methylheptane (DMHA), undeclared 1, 4-DMAA | weight loss | — | Alert |
| 2026-04-03 | Addall-brand dietary supplement ZMB Enterprises, LLC | Phenibut (β-phenyl-GABA), undeclared 1, 4-DMAA (1, 4-dimethylamylamine) | weight loss | — | Alert |
| 2026-03-26 | Gold Lion Aphrodisiac Chocolate Sachet Gear Isle | sildenafil, tadalafil | sexual enhancement | Gear Isle | Recall |
| 2026-03-14 | Boner Bear Honey Pure Vitamins and Natural Supplements, LLC | sildenafil, tadalafil | sexual enhancement | — | Recall |
| 2026-03-14 | Red Bull Extreme Pure Vitamins and Natural Supplements, LLC | sildenafil | sexual enhancement | — | Recall |
| 2026-03-14 | Blue Bull Extreme Pure Vitamins and Natural Supplements, LLC | sildenafil | sexual enhancement | — | Recall |
| 2026-03-13 | Kian Pee Wan Aphreseller | dexamethasone, cyproheptadine | other | ebay.com; buy-herbal.com | Public Notification |
| 2026-03-11 | Chupa Panza Naturista Reyes (Suerte Y Salud LLC, La Tia Mana LLC) | yellow oleander | other | ebay.com | Alert |
| 2026-03-03 | Artri Ajo Rey | dexamethasone, diclofenac, methocarbamol | other | naturistarex.com | Public Notification |
| 2026-02-26 | ULTRA ADVANC3 GOLD | dexamethasone, diclofenac, methocarbamol | other | naturistarex.com | Public Notification |
| 2026-02-26 | ULTRA ADVANC3 | dexamethasone, diclofenac, methocarbamol | other | amazon.com | Public Notification |
| 2026-02-13 | Green Lumber (update) Green Lumber Holdings LLC | tadalafil | sexual enhancement | getgreenlumber.com, greenlumber.com | Public Notification |
| 2026-02-13 | LOVION Chocolate with Ginseng for Men | sildenafil, tadalafil | sexual enhancement | lovionusa.com | Public Notification |
| 2026-02-13 | Fantasy Aphrodisiac Chocolate | sildenafil | sexual enhancement | gearisle.com | Public Notification |
| 2026-02-13 | DTF Sexual Chocolate Nalpac | sildenafil, tadalafil | sexual enhancement | shopsexology.com | Public Notification |
| 2026-02-13 | Boner Bears Chocolate Syrup Lockout Supplements | sildenafil | sexual enhancement | lockoutsupplements.com | Public Notification |
| 2026-02-13 | Boner Bears Chocolate Bar JXK Enterprises, Inc | sildenafil | sexual enhancement | elyxr.com | Public Notification |
| 2026-02-11 | Pink Pussycat Aphrodisiac Chocolate | tadalafil | sexual enhancement | loverslane.com | Public Notification |
| 2026-02-11 | Rhino Choco VIP USA LESS Co. | tadalafil | sexual enhancement | usaless.com | Public Notification |
| 2026-02-11 | ilum Male Sexual Enhancement Chocolate Gear Isle | sildenafil, tadalafil | sexual enhancement | ebay.com; Gear Isle | Public Notification |
| 2026-02-03 | Ashfiat Alharamain Akkarco LLC | tadalafil | sexual enhancement | akkarco.com; amazon.com | Recall |
| 2026-01-09 | Modern Warrior Ready Modern Warrior | tianeptine, 1, 4-DMAA, aniracetam | weight loss | — | Recall |
| 2025-12-02 | GE Labs Ykarine GE Labs LLC | trendione (estra-4, 9, 11-triene-3, 17-dione) | other | monsterking.eu | Alert |
| 2025-11-21 | mR.7 SUPER 700000 StuffbyNainax LLC | sildenafil, tadalafil | sexual enhancement | ebay.com | Public Notification |
| 2025-11-03 | SiluetaYa Mexican Tejocote Roots SiluetaYa, LLC | yellow oleander | other | siluetayausa.com | Recall |
| 2025-11-03 | SdB ELITE OBC Group Corp | yellow oleander | other | naturalvida.com | Alert |
| 2025-11-03 | SdB Semilla de Brasil Tejocote Root OBC Group Corp | yellow oleander | other | ebay.com | Alert |
| 2025-10-23 | SPARTAN | sildenafil | sexual enhancement | vroxusa.com | Public Notification |
| 2025-10-23 | vROX | sidenafil | sexual enhancement | vroxusa.com | Public Notification |
| 2025-10-17 | Black Thai Honey | sildenafil, tadafil, diclofenac | sexual enhancement | honeypack.com | Public Notiication |
| 2025-10-17 | Ashfiat Alharamain Energy Support | tadalafil | sexual enhancement | amazon.com | Public Notification |
| 2025-10-06 | Osteo Sin Max | dexamethasone, methocarbamol, phenylbutazone | other | ebay.com | Public Notification |
| 2025-10-06 | Mojo Max Fusion XXX | sildenafil, tadalafil | sexual enhancement | ebay.com | Public Notification |
| 2025-10-03 | Contra Reumas | dexamethasone, diclofenac, methocarbamol | other | naturistarex.com | Public Notification |
| 2025-09-30 | Me Vale Madre | acetaminophen, diclofenac | other | ebay.com | Public Notification |
| 2025-09-23 | Agebox iKids Growth Day Formula | ibutamoren | muscle building | agebox.com | Public Notification |
| 2025-09-23 | Agebox iKids Growth Night Formula | ibutamoren | muscle building | agebox.com | Public Notification |
| 2025-09-23 | Flexi Bion | dexamethasone, diclofenac | other | ebay.com | Public Notification |
| 2025-09-23 | SILINTAN 123Herbals | meloxicam | other | 123herbals.com | Public Notification |
| 2025-09-18 | Primal Herbs Volume Primal Supplements Group LLC | sildenafil | sexual enhancement | primalherbs.com | Public Notification |
| 2025-09-05 | FTX PLUS | dexamethasone phosphate, diclofenac | other | walmart.com | Public Notification |
| 2025-09-05 | REUMA KING | dexamethasone, diclofenac, methocarbamol | other | etsy.com | Public Notification |
| 2025-08-22 | PAIN FLEX NaTerra | dexamethasone, methocarbamol | other | amazon.com | Public Notification |
| 2025-07-22 | FATZorb Beauty Collection International Pte Ltd | sibutramine, desmethyl sibutramine, benzyl sibutramine, phenolphthalein | sexual enhancement, weight loss | ebay.com | Public Notification |
| 2025-07-08 | Versace Real Honey for Men Sekerciler Tic. ve San. Ltd. Sti. | sildenafil, tadalafil, acetaminophen | sexual enhancement | Various websites | Public Notification |
| 2025-07-08 | Black Horse Miracle Honey for Men Sekerciler Tic. ve San. Ltd. Sti. | sildenafil, tadalafil | sexual enhancement | Various websites | Public Notification |
| 2025-07-08 | Secret Miracle Honey Extra Strength Sekerciler Tic. ve San. Ltd. Sti. | sildenafil, tadalafil, acetaminophen | sexual enhancement | Various websites | Public Notification |
| 2025-07-08 | Black Panther Miracle Honey for Men Sekerciler Tic. ve San. Ltd. Sti. | sildenafil, tadalafil, acetaminophen | sexual enhancement | Various websites | Public Notification |
| 2025-06-24 | Toki Slimming Candy Hoang Huy Investment & Trading Co., Ltd. | sibutramine | weight loss | ebay.com | Public Notification |
| 2025-05-15 | Dolotrex Innovacion Natural | diclofenac | other | innvocaionnatural.com | Public Notification |
| 2025-05-15 | Umovy EREN NATURALS SA DE CV | dexamethasone, diclofenac | other | umovy-usa.com | Public Notification |
| 2025-05-15 | Unavy EREN NATURALS SA DE CV | dexamethasone, diclofenac, omeprazole | other | umary-usa.com | Public Notification |
| 2025-05-06 | Endurance Boost EnShiShiXiangNiShangMaoYouXianGongSi | propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Male Ultra Pro Health Fixer | chloropretadalafil, propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Ultra Armor Health Fixer | chloropretadalafil, propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Electro Buzz Health Fixer | chloropretadalafil, propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Malextra Health Fixer | chloropretadalafil, propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Male Ultra Health Fixer | chloropretadalafil, propoxyphenylsildenafil, sildenafil | sexual enhancement | amazon.com | Recall |
| 2025-04-25 | Artrifan King Omega Nutrition | dexamethasone, diclofenac, methocarbamol | other | artriking.us | Public Notification |
| 2025-04-23 | Pain Flex Forte NaTerra | dexamethasone, diclofenac | other | ibspot.com | Public Notification |
| 2025-02-10 | ADVANCE KING | dexamethasone, diclofenac, methocarbamol | other | naturistastore.com | Public Notification |
| 2025-02-10 | bio LIT | 1, 4-dimethylamylamine (DMAA) | weight loss | Various websites | Public Notification |
| 2025-02-10 | Special Edition Platinum 10K | acetaminophen, tadalafil, vardenafil | sexual enhancement | Various websites | Public Notification |
| 2025-02-10 | vROX | sildenafil | sexual enhancement | Various websites | Public Notification |
| 2025-02-10 | HimGo | sildenafil | sexual enhancement | ebay.com | Public Notification |
| 2025-02-10 | VITALITY One Source Nutrition | sildenafil, tadalafil | sexual enhancement | zen-herbs.com | Public Notification |
Older rows (1,298 products, 2007–2024) are in the open-data file. Each row’s FDA action link is the source for that row.
List 3: DoD prohibited dietary supplement ingredients
SourceOperation Supplement Safety (Uniformed Services University), DoD Prohibited Dietary Supplement Ingredients, prepared under DoD Instruction 6130.06. The page is a search box over an API with no download or published total; we crawled it on 2026-09-21 with 3,000 queries and reached 850 ingredient entries (4,420 names including synonyms). The crawl hit its request budget before the queue was empty, so the count is a lower bound, not the whole list. OPSS states the list was last updated on 26 May 2026.
Service members are prohibited from using any substance in this database as a supplement ingredient, and separately from all controlled substances and drugs. The reasons OPSS attaches to entries, by count: DEA Controlled Substance List: Schedule I (283), DEA Controlled Substance List: Schedule III (110), WADA S1: Anabolic Agents (110), DEA Controlled Substance List: Schedule IV (80), DEA Controlled Substance List: Schedule II (62), Prescription drug (62).
Showing 850 of 850 entries
| Ingredient | Also listed as | Reason | Reference |
|---|---|---|---|
| 1-(1-phenylcyclohexyl)-pyrrolidine | PCPy; PHP; rolicyclidine; pyrrolidine analog of phencyclidine; 1-(1-Phenylcyclohexyl)pyrrolidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-(5-fluoropentyl)-3-(1-naphthoyl)indole | AM2201; AM-2201; AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole | AM-694; AM694 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-[1-(2-thienyl)cyclohexyl]piperidine | TPCP; 1-[1-(2-thienyl)-cyclohexyl]-piperidine; TCP; thiophene analog of phencyclidine; 2-thienylanalog of phencyclidine (+1) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-[1-(2-thienyl)cyclohexyl]pyrrolidine | TCPy | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole | JWH-200; JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1- naphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-androstenediol | 3β,17β-dihydroxy-5α-androst-1-ene; 3alpha,17beta-dihydroxy-5alpha-androst-1-ene; 3beta,17beta-dihydroxy-5alpha-androst-1-ene; 5α-androst-1-ene-3β,17β-diol; 5alpha-androst-1-ene-3beta,17beta-diol (+1) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 1-androstenedione | 5ɑ-androst-1-ene-3ß, 17ß-dione; 5α-androst-1-ene-3,17-dione; [5α]-androst-1-en-3,17-dione; 5alpha-androst-1-ene-3,17-dione | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 1-androsterone | androst-1-en-17-one, 3-hydroxy-, (3β,5α)-; 1-androstenolone; (3beta,5alpha)-3-hydroxyandrost-1-en-17-one; 3β-hydroxy-5α-androsta-1-ene-17-one; 1-androstene-3beta-ol, 17-one (+24) | WADA S1: Anabolic Agents | OPSS entry |
| 1-butyl-3-(1-naphthoyl)indole | JWH-073; JWH-073 (1-Butyl-3-(1-naphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-hexyl-3-(1-naphthoyl)indole | JWH-019; JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-(1-naphthoyl)indole | AM-678; AM678; JWH-018 (also known as AM678) (1-Pentyl-3-(1- naphthoyl)indole); JWH-018 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-(2-chlorophenylacetyl)indole | 2-(2-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; JWH-203; JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-(2-methoxyphenylacetyl)indole | 2-(2-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; JWH-250 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-(4-chloro-1-naphthoyl)indole | JWH-398; (4-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone; JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-(4-methyl-1-naphthoyl)indole | (4-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone; JWH-122; JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole | 1-pentyl-3-(4-methoxynaphthoyl)indole; JWH-081; (4-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone; JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 1-phenylcyclohexylamine | 1-phenylcyclohexan-1-amine | DEA Controlled Substance List: Schedule II | OPSS entry |
| 1-testosterone | 1-Testo; 17β-hydroxy-5α-androst-1-en-3-one; Δ1-dihydrotestosterone (17β-hydroxy-5α-androst-1-en3-one); Δ1-dihydrotestosterone; 1-testosterone acetate (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 11-keto-testosterone | 17beta-hydroxy-androst-4-en-3,11-one; 17β-Hydroxy-androst-4-en-3,11-one | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| 11β-methyl-19-nortestosterone | 11β-methylestr-4-en-17β-ol-3-one; 11beta-methylestr-4-en-17beta-ol-3-one; 11β-MNT; 11beta-MNT; 11beta-methyl-19-nortestosterone (+1) | WADA S1: Anabolic Agents | OPSS entry |
| 13β-ethyl-17β-hydroxygon-4-en-3-one | 18-methyl-19-nortestosterone; 13beta-ethyl-17beta-hydroxygon-4-en-3-one; 17beta-hydroxy-13-ethylgon-4-en-3-one | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17-dihydroexemestane | 17beta-hydroxy exemestane; 17β-hydroxy exemestane; methylene boldenone; 6-methylene-17-hydroxyandrosta-1,4-diene-3-one; androsta-1,4-dien-3-one, 17-hydroxy-6-methylene- (+4) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 17alpha-methyl-3beta,17beta-dihydroxy-5alpha-androstane | 17-methyl-5α-androstane-3β,17β-diol; 17-methyl-5alpha-androstane-3beta,17beta-diol; 17α-methyl-3β,17β-dihydroxy-5α-androstane | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-3beta,17beta-dihydroxyandrost-4-ene | 17-methyl-androst-4-ene-3beta,17beta-diol; 17-methyl-androst-4-ene-3β,17β-diol; 17-methylandrost-4-ene-3beta,17beta-diol; 17-methylandrost-4-ene-3β,17β-diol; 17α-methyl-3β,17β-dihydroxyandrost-4-ene | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-4-hydroxynandrolone | 17alpha-methyl-4-hydroxy-17beta-hydroxyestr-4-en-3-one; 4-hydroxy-19-normethyltestosterone; 17α-methyl-4-hydroxynandrolone; estr-4-en-3-one, 4,17β-dihydroxy-17-methyl-; 17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one (+2) | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-5alpha-androstan-17beta-ol | protobol; 17a-methyl-5a-androst-17b-ol; 17-methyl-5α-androstan-17β-ol; 17α-methyl-5α-androstan-17β-ol; protodrol (+1) | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-androst-2-ene-3,17beta-diol | 17α-methyl-androst-2-ene-3,17β-diol; 17a-methyl-androst-2-ene-3,17b-diol | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-androsta-1,4-diene-3,17beta-diol | 17a-methyl-1,4-androstadiene-3,17diol; 17alpha-methyl-1,4-androstadiene-3,17diol; methyl-1,4AD; 17α-methyl-1,4-androstadiene-3,17diol; M1,4ADD (+6) | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17alpha-methyl-androstan-3-hydroxyimine-17beta-ol | 17α-methyl-androstan-3-hydroxyimine-17β-ol; 17a-Methyl-androstan-3-hydroxyimine-17b-ol | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17beta-hydroxy-androstano[2,3-d]isoxazole | 17β-hydroxy-androstano[2,3-d]isoxazole; 17b-Hydroxy-androstano[2,3-d]isoxazole | DEA Controlled Substance List: Schedule III | OPSS entry |
| 17beta-hydroxy-androstano[3,2-c]isoxazole | 17β-hydroxy-androstano[3,2-c]isoxazole; 17b-Hydroxy-androstano[3,2-c]isoxazole | DEA Controlled Substance List: Schedule III | OPSS entry |
| 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one | DEA Controlled Substance List: Schedule III | OPSS entry | |
| 19-nor-4,9(10)-androstadienedione | methyldienedione; estra-4,9-diene-3,17-dione; 4,9-esteadine-3,17-dione; estra-4,9-dien-3,17-dione; dienedione (+8) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 19-nor-5-androstenediol | 3alpha,17beta-dihydroxyestr-5-ene; 3α, 17β-dihydroxyestr-5-ene; 3β, 17β-dihydroxyestr-5-ene; 3beta,17beta-dihydroxyestr-5-ene | DEA Controlled Substance List: Schedule III | OPSS entry |
| 19-nor-5-androstenedione | 19-norandrost-5-en-3,17-dione; 19-norandrost-5-ene-3,17-dione; estr-5-en-3,17-dione; estr-5-ene-3,17-dione | DEA Controlled Substance List: Schedule III | OPSS entry |
| 19-norandrosterone | 5α-estran-3α-ol-17-one; 19-nor-androsterone; 3alpha-hydroxy-5alpha-estran-17-one; 3α-hydroxy-5α-estran-17-one; 5alpha-estran-3alpha-ol-17-one | WADA S1: Anabolic Agents | OPSS entry |
| 2',5'-dimethoxyfentanyl | N-(1-(2,5- dimethoxyphenethyl)piperidine-4-yl)-N-phenylpropionamide; N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2,5-dimethoxyamphetamine | 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA; DMA | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one | 2-(3-dethoxyphenyl)-2-(N-ethylamino)cyclohexanone; 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone; 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone; 2-(ethylamino)-2-(3-methoxyphenyl)-1-cyclohexanone; 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone (+6) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2-androstenol | 5alpha-androst-2-en-17-ol; 5α-androst-2-en-17-ol | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 2-androstenone | 17-oxo-5α-androst-2-ene; 17-oxo-5a-androst-2-ene; 5 α androst-2-en- 17-one; 17-oxo-5alpha-androst-2-ene; delta-2 (+5) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 2-Phenylbenzo[h]chromen-4-one | 7,8-benzoflavone; 2-phenylbenzo[h]chromen-4-one; alpha-naphthoflavone; ɑ-naphthoflavone | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 25B-NBOMe | 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Cimbi-36; 2C-B-NBOMe; 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 25C-NBOMe | 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine; 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 2C-C-NBOMe; Cimbi-82; 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 25I-NBOMe | Cimbi-5; 2C-I-NBOMe; 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-C | 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine; 2-(4-chloro-2,5-dimethoxyphenyl) ethanamine; 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C-C) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-D | 2-(2,5-dimethoxy-4-methylphenyl) ethanamine; 2-(2,5-dimethoxy-4-methylphenyl)ethanamine; 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C-D) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-E | 2,5-Dimethoxy-3,4-dimethylphenethylamine (2C-G); 2-(2,5-dimethoxy-4-ethylphenyl) ethanamine; 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine; 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C-E) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-H | 2-(2,5-dimethoxyphenyl)ethanamine; 2-(2,5-dimethoxyphenyl) ethanamine; 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-I | 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine; 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine; 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-N | 2-(2,5-dimethoxy-4-nitro-phenyl) ethanamine; 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine; 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C-N) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-P | 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2-CP); 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine; 2-(2,5-dimethoxy-4-(n)-propylphenyl) ethanamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-T-2 | 2-[4-(ethylthio)-2,5-dimethoxyphenyl] ethanamine; 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine; 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C-T-2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-T-4 | 2,5-Dimethoxy-4-ethylthioamphetamine; 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine; 2,5-Dimethoxy-4-ethylthioamphetamine (Aleph-2); Aleph-2; 2-[4-(isopropylthio)-2,5-dimethoxyphenyl] ethanamine (+1) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2C-T-7 | 2,5-dimethoxy-4(n)-propylthiophenethylamine; 2,5-dimethoxy-4-(n)-propylthiophenethylamine; 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 2′-fluoro ortho-fluorofentanyl | 2'-Fluoro ortho-fluorofentanyl (N-(1-(2- fluorophenethyl)piperidin-4-yl)-N-(2- fluorophenyl)propionamide; also known as 2'-fluoro 2- fluorofentanyl); N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide; 2′-fluoro 2-fluorofentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3,4-dimethylmethcathinone | 3,4-DMMC | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3-androstenol | 3-Androstenol (5ɑ-androst-3-en-17-ol); 5α-androst-3-en-17-ol; 5alpha-androst-3-en-17-ol | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 3-fluoro-N-methylcathinone | 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one); 3-Fluoro-N-methylcathinone (3-FMC) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3-furanyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide; N-(1-phenthylpiperidin-4-yl)-N-phenylfuran-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3-methylethcathinone | 3-MEC | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3-methylfentanyl | 3-MF; mefentanyl; China White; N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3-methylthiofentanyl | N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide; N-[3-methyl-1-(2-thienylethyl)-4-piperidinyl]-N-phenylpropanamide; 3-methyl-thiofentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| 3beta-hydroxy-estra-4,9,11-trien-17-one | 3β-hydroxy-estra-4,9,11-trien-17-one; 3b-hydroxy-estra-4,9,11-trien-17-one | DEA Controlled Substance List: Schedule III | OPSS entry |
| 4'-chloro-alpha-PVP | 4'-chloro-α-pyrrolidinopentiophenone; 4-chloro-a-PVP; 4'-chloro-α-pyrrolidinovalerophenone; 4-chloro-α-PVP; 4'-chloro-alpha-pyrrolidinopentiophenone (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4,4′-Dimethylaminorex | 4,5-Dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine; 4,4′-DMAR; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2- F][1,2,4]triazolo[4,3-A][1,4]diazepine | etizolam | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-androstene-3,6,17 trione | 4-Androstene-3,6,17-trione; 6-oxo-androstenedione; 4-androsten-3,6,17-trione; 6-oxo; 4-AT (+2) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 4-androstenediol | 3beta,17beta-dihydroxy-androst-4-ene; androst-4-ene-3β,17β-diol; 3β,17β-dihydroxy-androst-4-ene | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 4-anilino-N-phenethylpiperidine | 4-anilino-N-phenethyl-4-piperidine; N-phenyl-1-(2-phenylethyl)piperidin-4-amine; 1-phenethyl-N-phenylpiperidin-4-amine; despropionylfentanyl; 4-Anilino-N-phenethyl-4-piperidine (ANPP) (+2) | DEA Controlled Substance List: Schedule II | OPSS entry |
| 4-bromo-2,5-dimethoxyphenethylamine | alpha-desmethyl DOB; Nexus; 2C-B; 2-(4-bromo-2,5-dimethoxyphenyl)ethylamine; 4-bromo-2,5-dimethoxyphenethylamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-fluoro-N-methylcathinone | 1-(4-fluorophenyl)-2-(methylamino)propan-1-one); flephedrone; 2-FMC; 4-FMC; 4-Fluoro-N-methylcathinone (4-FMC) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-fluoroisobutyryl fentanyl | p-fluoroisobutyrfentanyl; N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide; para-fluoroisobutyryl fentanyl; P-FIBF | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-fluoromethylphenidate | (±)-threo-4-fluoromethylphenidate; 4-FMPH; 4F-MPH | Unapproved Drug | NIH NCATS Inxight Drugs entry: 4-fluoromethylphenidate |
| 4-hydroxytestosterone | 4,17beta-dihydroxy-androst-4-en-3-one; 4,17β-dihydroxyandrost-4-en-3-one; 4,17beta-dihydroxyandrost-4-en-3-one; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); 4,17β-dihydroxy-androst-4-en-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 4-MEAP | 4-methyl-alpha-ethylaminopentiophenone; 4-methyl-α-ethylaminopentiophenone; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one; 4-methyl-alpha-ethylaminopentiophenone (4-MEAP) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-MePPP | 4-methyl-alphapyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one); 4-methyl-alpha-pyrrolidinopropiophenone; 4-methyl-α-pyrrolidinopropiophenone; 4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-methoxyamphetamine | 4-methoxy-α-methylphenethylamine; PMA; p-methoxyamphetamine; 1-(4-methoxyphenyl)propan-2-amine; paramethoxyamphetamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-methyl-N-ethylcathinone | 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; 4-EMC; EMC; 4-ethylmethcathinone (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-methylaminorex, cis-(+/-)- | U4Euh; 4-methylaminorex (cis isomer); (±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine; (±)cis-4-methylaminorex; McN-422 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-methylamphetamine | 4-MA; p-methylamphetamine; p-methylamfetamine | Unapproved Drug; DoDI 1010.16 | NIH NCATS Inxight Drugs entry: 4-methylamphetamine |
| 4-methylbuphedrone | 4-MeMABP; 4-MeBP | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4-OH-DiPT | 4-hydroxy-N,N-diisopropyltryptamine | Other reason | DoDI 1010.04 Problematic Substance Use by DoD Personnel |
| 4F-MDMB-BINACA | methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4F-MDMB-BUTICA | 4fluoro-MDMB-BUTICA; methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| 4′-methyl acetyl fentanyl | N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | CP-47,497 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | CP-47,497 C8-homolog; cannabicyclohexanol | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-alpha-hydroxy-laxogenin | Biobras 16; BB-16; spirostan-6-one, 3,5-dihydroxy-, (3b,5a,25R)-; 25-R-spirostan-5a-diol-6-one-3-one; 25R,5α-spirostan-3β,5-diol-6-one (+12) | FDA Warning Letter | FDA Warning Letter: Does not meet the definition of a dietary ingredient |
| 5-androstenedione | 5-androsten-3,17-dione; androst-5-en-3,17-dione; androst-5-ene-3,17-dione | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| 5-fluoro-PB-22 | 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester; 5F-PB-22; quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-fluoro-UR-144 | [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; XLR-11; XLR11 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-MeO-AMT | 5-methoxy-alpha-methyltryptamine | Other reason | DoDI 1010.04 Problematic Substance Use by DoD Personnel |
| 5-MeO-DET | 5-methoxy-N,N-diethyltryptamine | Other reason | DoDI 1010.04 Problematic Substance Use by DoD Personnel |
| 5-MeO-DIPT | Foxy methoxy; FOXY; 5-methoxy-N,N-dipropyltryptamine; 5-MeO-DPT; 5-methoxy-N,N-diisopropyltryptamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-MeO-DMT | methylbufotenine; 5-methoxy-N,N-dimethyltryptamine; 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 4-methoxy-N,N-dimethyltryptamine; 4-MeO-DMT (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5-MeO-MiPT | 5-methoxy-N-methyl-N-isopropyltryptamine | Other reason | DoDI 1010.04 Problematic Substance Use by DoD Personnel |
| 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine | BAM15; 5-N,6-N-bis(2- fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 5alpha-androstan-3,6,17-trione | 5alpha-androstane-3,6,17-trione; 5α-androstane-3,6,17-trione; 5α-androstan-3,6,17-trione | DEA Controlled Substance List: Schedule III | OPSS entry |
| 5F-AB-PINACA | 5-fluoro-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-ADB | 5F-EMB-PINACA; methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; 5F-MDMB-PINACA; 5-fluoro-ADB; 5F-AEB | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-AMB | methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; 5-fluoro-AMB; 5-fluoro-AMP; 2-(1-(5-Fluoropentyl)-1H-indazole-3-ylcarbonylamino)-3-methylbutanoic acid methyl ester | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-APINACA | N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; 5F-AKB48 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-CUMYL-P7AICA | 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-CUMYL-PINACA | 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; SGT-25 | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-EDMB-PICA | 5fluoro-EDMB-PICA; ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate; ethyl 2-[[1-(5-fluorophentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-EDMB-PINACA | ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| 5F-MDMB-PICA | 5-fluoro-EMB-PICA; 5F-MDMB-2201; 5FMDMB-PICA; 5F-EMB-PICA; methyl 2-(1-(5-fluoropentyl)-1Hindole-3-carboxamido)-3,3-dimethylbutanoate (+1) | DEA Controlled Substance List: Schedule I | OPSS entry |
| 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo[F][1,2,4]triazolo[4,3-A][1,4]diazepine | clonazolam | DEA Controlled Substance List: Schedule I | OPSS entry |
| 6-bromo-androsta-1,4-diene-3,17-dione | 6-bromo boldione; 6-bromoandrosta-1,4-diene-3,17-dione; 6-bromo-androstan-1,4-diene-3,17-dione | DEA Controlled Substance List: Schedule III; WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| 6-bromo-androstan-3,17-dione | DEA Controlled Substance List: Schedule III | OPSS entry | |
| 6-monoacetylmorphine | 6-MAM | DoDI 1010.16 | OPSS entry |
| 6alpha-methyl-androst-4-ene-3,17-dione | 6α-methylandrostenedione; 6alpha-methylandrostenedione; 6α-methyl-androst-4-ene-3,17-dione; 6α-methyl-androst-4-en-3,17-dione | DEA Controlled Substance List: Schedule III | OPSS entry |
| 7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro- 2H-benzo[E][1,4]diazepin-2-one | diclazepam | DEA Controlled Substance List: Schedule I | OPSS entry |
| 7-isopropoxyisoflavone | 7-isopropoxy-3-phenyl-4H-chromen-4-one; Ipriflavone; Osten | Unapproved Drug | NIH NCATS Inxight Drugs entry: Ipriflavone |
| 7-keto DHEA | 7-keto-dehydroepiandrosterone; 3β-hydroxyandrost-5-ene-7,17-dione; 7-keto-DHEA; 7-oxodehydroepiandrosterone; 7-oxo-DHEA (+2) | WADA S1: Anabolic Agents; Military policy | DoDI 6130.06 Use of Dietary Supplements in the DoD |
| 7alpha-hydroxy-DHEA | 7α-hydroxy-DHEA (C.S.); 7-hydroxy-DHEA; 7-hydroxydehydroepiandrosterone; 7a-hydroxy-dehydroepiandrosterone; 7alpha-hydroxydehydroepiandrosterone (+7) | WADA S1: Anabolic Agents | OPSS entry |
| 7beta-hydroxy-DHEA | 7β-hydroxy-DHEA; 7b-hydroxydehydroepiandrosterone | WADA S1: Anabolic Agents | OPSS entry |
| 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[F][1,2,4]trazolo[4,3-A][1,4]diazepine | flubromazolam | DEA Controlled Substance List: Schedule I | OPSS entry |
| 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[F][1,2,4]triazolo[4,3-A][1,4]diazepine | flualprazolam | DEA Controlled Substance List: Schedule I | OPSS entry |
| 9-hydroxyfluorene | fluorenol; hydrafinil; fluoren-9-ol; 9-fluorenol; 9 fluorenol | WADA S6: Stimulants | OPSS entry |
| [3,2-c]-furazan-5alpha-androstan-17beta-ol | [3,2-c]-furazan-5α-androstan-17β-ol | DEA Controlled Substance List: Schedule III | OPSS entry |
| [3,2-c]pyrazole-androst-4-en-17beta-ol | [3,2-c]pyrazole-androst-4-en-17β-ol | DEA Controlled Substance List: Schedule III | OPSS entry |
| AB-CHMINACA | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| AB-FUBINACA | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| AB-PINACA | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| AC-262536 | AC-262,536; 4-(3-endo-hydroxy-8-azabicyclo(3.2.1)oct-8-yl)naphthalene-1-carbonitrile | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| Acacia rigidula | Chaparro prieto; Acaciopsis rigidula; blackbrush acacia; Acacia rigidula extract (98%); Vachellia rigidula (+2) | FDA Statement | FDA: Acacia rigidula in Dietary Supplements |
| ACE-031 | Ramatercept | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| acetazolamide | acetazolamide sodium | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Acetazolamide |
| acetorphine | 7alpha-etorphine 3-acetate | DEA Controlled Substance List: Schedule I | OPSS entry |
| acetyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide; acetylfentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| acetyl-alpha-methylfentanyl | acetyl-α-methylfentanyl; alphamethylacetylfentanyl; N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| acetyldihydrocodeine | dihydrothebacone; dihydrocodeine 6-acetate | DEA Controlled Substance List: Schedule I | OPSS entry |
| acetylmethadol | acemethadone; methadyl acetate | DEA Controlled Substance List: Schedule I | OPSS entry |
| acetylpsilocin | O-acetylpsilocin ; 4-AcO-DMT; psilacetin; 4-acetoxy-N,N-dimethyltryptamine; 4-acetoxy-DMT | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| Aconitum | aconite root; queen of poisons; mousebane; leopard's bane; wolfsbane (+12) | Other reason | NIH NCATS Inxight Drugs entry: Aconitine |
| ACP-105 | 2-chloro-4-[(1R,5R)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1] octan-8-yl]-3-methylbenzonitrile; 2-chloro-4-[(1R,5S)-3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl]-3-methylbenzonitrile; Acadibol | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| acryl fentanyl | acryloylfentanyl; acrylfentanyl; N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| adamantoyl | AB-001; 1-pentyl-3-(1-adamantoyle)indole | DoDI 1010.16 | OPSS entry |
| ADB-4en-PINACA | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ADB-BUTINACA | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ADB-FUBINACA | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ADB-PINACA | N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| adrafinil | benzhydrylsulfinylacetohydroxamic acid; 2-((diphenylmethyl)sulfinyl)acetohydroxamsaeure; Noofon; 2-((diphenylmethyl)sulfinyl)acetohydroxamic acid; acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)- (+7) | FDA Statement | FDA Statement |
| adrenosterone | 11-keto-androstenedione; androst-4-ene-3,11,17-trione; 11-OXO; andrenosterone; 4-androstene-3,11,17-trione (+6) | WADA S1: Anabolic Agents | OPSS entry |
| aegeline | aegelin; N-2-hydroxy-2(4-methoxyphenyl) ethyl-3-phenyl-2-propenamide; egeline | FDA Warning Letter | FDA warning letter: New dietary ingredient lacking evidence for safe use; associated adverse events reported |
| AH-7921 | 3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| AICAR | 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide monophosphate; 5-amino-4-imidazolecarboxamide ribofuranoside 5'-monophosphate; AICA ribonucleotide; NSC 283955; AICA ribonucleotide, (D-ribofuranosyl)-isomer (+11) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| alexamorelin | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| alfaxalone | 5alpha-pregnan-3alpha-ol-11,20-dione; Alfaxan | DEA Controlled Substance List: Schedule IV | OPSS entry |
| alfentanil | alfentanyl; Alfenta; N-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide | DEA Controlled Substance List: Schedule II | OPSS entry |
| allylprodine | alperidine; 4-piperidinol, 1-methyl-4-phenyl-3-(2-propenyl)-, propanoate (ester) | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha'-methyl butyryl fentanyl | 2-methyl-N-(1phenethylpiperidin-4-yl)-N-phenylbutanamide; α'-methyl butyryl fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-ethyltryptamine | ET; etryptamine; Trip; α-ethyltryptamine; Monase (+5) | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-methylfentanyl | N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; α-methylfentanyl; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-methylthiofentanyl | N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide; α-methylthiofentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-methyltryptamine | 3-(2-aminopropyl)indole; AMT; N-methyltryptamine; Indopan; α-methyltryptamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-PHP | alpha-pyrrolidinohexiophenone; α-PHP; alpha-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-PiHP | 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one; α-PiHP | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-pyrrolidinobutiophenone | alpha-PBP; α-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| alpha-pyrrolidinopentiophenone | flakka; α-pyrrolidinovalerophenone; 1-phenyl-2- (pyrrolidin-1-yl)pentan-1-one; 1-phenyl-2-(piperidin-1-yl)butan-1-one); α-PVP (+4) | DEA Controlled Substance List: Schedule I | OPSS entry |
| alphacetylmethadol | alphacemethadone; alpha-3-acetoxy-6-dimethylamino-4,4-diphenylheptane; alphacetylmathadol | DEA Controlled Substance List: Schedule I | OPSS entry |
| alphameprodine | 3alpha-ethyl-1-methyl-4-phenyl-4alpha-piperidyl propionat; 3α-ethyl-1-methyl-4-phenyl-4α-piperidyl propionat | DEA Controlled Substance List: Schedule I | OPSS entry |
| alphamethadol | alpha-methadol | DEA Controlled Substance List: Schedule I | OPSS entry |
| alphaprodine | prodine; 1,3-dimethyl-4-phenyl-4-propionoxypiperidine; Nisentil | DEA Controlled Substance List: Schedule II | OPSS entry |
| alprazolam | α-hydroxy-alprazolam; Xanax | DEA Controlled Substance List: Schedule IV | OPSS entry |
| Amanita muscaria | fly agaric mushroom; ibotenic acid; muscarine; muscimol | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| AMB-FUBINACA | methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; FUB-AMB; MMB-FUBINACA | DEA Controlled Substance List: Schedule I | OPSS entry |
| amfetaminil | amphetaminil; AN-1; N-cyanobenzylamphetamine | Unapproved Drug; DoDI 1010.16 | NIH NCATS Inxight Drugs entry: Amfetaminil |
| amiloride | Midamor | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Amiloride |
| amineptine | (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid) | DEA Controlled Substance List: Schedule I | OPSS entry |
| aminoglutethimide | Cytadren; 3-(4-Aminophenyl)-3-ethylpiperidine-2,6-dione | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| aminorex | 4,5-dihydro-5-phenly-2-oxazolamine; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; Apiquel | DEA Controlled Substance List: Schedule I | OPSS entry |
| amobarbital | Amobarbital & noncontrolled active ingred.; isoamylethylbarbituric acid; 5-ethyl-5-isoamylbarbituric acid; Amytal | DEA Controlled Substance List: Schedule II; DEA Controlled Substance List: Schedule III | OPSS entry |
| amphetamine | 1-methyl-2-phenylethylamine; Obetrol; desoxynorephedrine; alpha-methylphenethylamine; Dexedrine (+4) | DEA Controlled Substance List: Schedule II | OPSS entry |
| anamorelin | RC-1291; 3-piperidinecarboxylic acid, 1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-, trimethylhydrazide, (3R)- | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| anastrozole | Arimidex; 2-[3-(2-Vyanopropan-2-yl)-5-(1,2,4-triazol-1- ylmethyl)phenyl]-2-methylpropanenitrile | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Anastrozole |
| andarine | acetamidoxolutamide; (2S)-3-(4-acetamidophenoxy)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide; propanamide, 3-(4-(acetylamino)phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-, (2S)-; 3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)propionamide; SARM S-4 (+9) | WADA S1: Anabolic Agents; FDA Statement | NIH NCATS Inxight Drugs entry: Andarine |
| androsta-3,5-diene-7,17-dione | 3,5-androstadiene-7,17-dione; androst-3,5-diene-7,17-dione; androst-3,5-dien-7,17-dione; arimistane; 3-deoxy-7-oxo-DHEA (+1) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| androstadienone | delta4,16-androstadien-3-one; Δ4,16-androstadien-3-one; androsta-4,16-dien-3-one; 4,16-androstadien-3-one | WADA S1: Anabolic Agents | OPSS entry |
| androstanediol | 3α,17β-dihydroxy-5α-androstane; 3alpha-androstanediol; 3alpha,17beta-dihydroxy-5alpha-androstane; 5-α-androstan-3-α,17-β-diol; 3α-androstanediol (+3) | DEA Controlled Substance List: Schedule III | OPSS entry |
| androstanedione | 5α-androstan-3,17-dione; 5α-androstane-3,17-dione; 5alpha-androstane-3,17-dione; 5alpha-androstan-3,17-dione | DEA Controlled Substance List: Schedule III | OPSS entry |
| androstanolone | dihydrotestosterone; 5α-dihydrotestosterone; DHT; 17beta-hydroxy-5alpha-androstan-3-one; 5α-DHT (+9) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| androstatrienedione | ATD; 1,4,6-androstatriene-3,17-dione; 3,17-keto-etiocholetriene; androsta 1,4,6 triene 3,17 dione; androst-1,4,6-triene-3,17-dione (+2) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| androstenediol | 5-androstene-3β-17β-diol; 3β,17β-dihydroxy-androst-5-ene; 3beta,17beta-dihydroxy-androst-5-ene; androst-5-ene-3,17-diol; 5-androstenediol (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| androstenedione | Δ4-androstenedione; 17-ketotestosterone; 4-androstene-3,17-dione; Adione; 4-androstenedione (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| androsterone | 3alpha-hydroxyetioallocholan-17-one; 5alpha-androsterone; 5α-androsterone; 3-epihydroxyetiollocholan-17-one; 5alpha-androstane-3alpha-ol-17-one (+6) | WADA S1: Anabolic Agents | OPSS entry |
| anileridine | Leritine; Alidine; Nipecotan; Adopol; ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate (+1) | DEA Controlled Substance List: Schedule II | OPSS entry |
| aniracetam | 1-anisoyl-2-pyrrolidinone; 1-(4-methoxybenzoyl)-2-pyrrolidinone; Draganon; 1-P-anisoyl-2-pyrrolidinone; Sarpul | FDA Statement | FDA Statement |
| APINACA | N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; AKB48 | DEA Controlled Substance List: Schedule I | OPSS entry |
| apitegromab | WADA S4: Hormone and Metabolic Modulators | OPSS entry | |
| aprobarbital | Alurate | DEA Controlled Substance List: Schedule III | OPSS entry |
| Areca catechu nut | areca nut; betel nut; Areca catechu extract; arecoline | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| arformoterol | formoterol R,R-form | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Arformoterol |
| asialo EPO | asialo erythropoietin; asialo-erythropoietin; ASIALO-EPO | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| barbital | Plexonal; barbitone; Veronal; 5,5-diethylbarbituric acid | DEA Controlled Substance List: Schedule IV | OPSS entry |
| barbituric acid | Malonylurea; barbituric acid derivative; 6-hydroxyuracil; barbiturates not specifically listed | DEA Controlled Substance List: Schedule III | OPSS entry |
| bazedoxifene | WAY 140424; TSE-424; Bazedoxifeno; bazedoxifene acetate; WAY140424 (+6) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Bazedoxifene |
| bendroflumethiazide | Naturetin; bendrofluazide; Aprinox | WADA S5: Diuretics and Masking Agents | OPSS entry |
| benzethidine | ethyl 1-(2-benzyloxyethyl)-4-phenylpiperidine-4-carboxylate | DEA Controlled Substance List: Schedule I | OPSS entry |
| benzimidazole | 1,3-benzodiazole; 1H-benzimidazole | DoDI 1010.16 | OPSS entry |
| benzoylecgonine | 3-(benzoyloxy)-8-methyl-8-azabicyclo(3.2.1)octane-2-carboxylic acid; ecgonine benzoate | DoDI 1010.16 | OPSS entry |
| benzphetamine | Didrex; benzfetamine; (R,S)-N-benzyl-alpha,N-dimethylphenethylamin; d-benzphetamine; Inapetyl | DEA Controlled Substance List: Schedule III | OPSS entry |
| benzylmorphine | 3-benzyloxy-4,5alpha-epoxy-17-methyl-7-morphinen-6alpha-ol; O3-benzylmorphine | DEA Controlled Substance List: Schedule I | OPSS entry |
| beta'-phenyl fentanyl | β′-phenyl fentanyl; beta'-phenyl fentanyl; N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide; 3-phenylpropanoyl fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| beta-hydroxy-3-methylfentanyl | N-[1-(2-hydroxy-2-phenylethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| beta-hydroxyfentanyl | N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| beta-hydroxythiofentanyl | N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide; N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| beta-methyl fentanyl | β-methyl fentanyl ; N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| betacetylmethadol | (3S,6R)-3-acetoxy-6-dimethylamino-4,4-diphenylheptane; beta-1-ethyl-4-dimethylamino-2,2-diphenylpentyl acetat; betacemethadon; beta-3-acetoxy-6-dimethylamino-4,4-diphenylheptane | DEA Controlled Substance List: Schedule I | OPSS entry |
| betameprodine | NU-1932 | DEA Controlled Substance List: Schedule I | OPSS entry |
| betamethadol | DEA Controlled Substance List: Schedule I | OPSS entry | |
| betaprodine | beta-1,3-dimethyl-4-phenyl-4-propionyloxypiperidine; beta-prodine; [(3R,4R)-1,3-dimethyl-4-phenylpiperidin-4-yl] propanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| bezitramide | Burgodin | DEA Controlled Substance List: Schedule II | OPSS entry |
| bimagrumab | human anti-ACTRIIB monoclonal antibody | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| bismuth nitrate | bismuth(III) nitrate pentahydrate; bismuth trinitrate pentahydrate; nitric acid, bismuth(3+) salt; bismuth trinitrate; bismuth(III) nitrate | OTC drug | NIH NCATS Inxight Drugs entry: Bismuth nitrate |
| BMPEA | beta-phenylpropylamine; B-Methylphenethylamine; ß-MePEA; 1-propanamine, 2-phenyl-; R-beta methylphenylethylamine (+23) | FDA Statement | FDA: BMPEA in Dietary Supplements |
| BMS-564929 | benzonitrile, 2-chloro-3-methyl-4-((7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo(1,2-C)imidazol-2(3H)-yl)-; BMS-564,929 | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| bolasterone | 7alpha,17alpha-dimethyltestosterone; 7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one; 7alpha,17alpha-dimethyl-17betahydroxyandrost-4-en-3-one; 7α,17α-dimethyltestosterone | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| boldenone | 1,4-androstadiene-3-one-17beta-ol; Parenabol; Equigan; Ganabol; 1,4-androstadiene-17-beta-ol-3-one (+11) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| boldione | 1,4-AD; androsta-1,4-diene-3,17-dione; androstadienedione | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| BPC-157 | PL-14736; Bepecin; body protection compound | WADA S0: Non-approved Substances | OPSS entry |
| bremelanotide | PT-141 | Prescription drug | NIH NCATS Inxight Drugs: Bremelanotide |
| brexanolone | allopregnan-3alpha-ol-20-one; allopregnanolone; 3α-hydroxy-5α-pregnan-20-one; allotetrahydroprogesterone | DEA Controlled Substance List: Schedule IV | OPSS entry |
| brivaracetam | UCB-34714; BRV; Briviact; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | DEA Controlled Substance List: Schedule V | OPSS entry |
| brolamfetamine | 4-bromo-2,5-DMA; 4-bromo-2,5-dimethoxy-amphetamine; 4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-DMA | DEA Controlled Substance List: Schedule I | OPSS entry |
| bromazepam | 7-bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one; Lexotanil; Lexatin; Durazanil; Compedium (+1) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| brorphine | 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one; 1-[1-[1-(4-bromophenyl)ethyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| bufotenine | 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; mappine; 3-(β-Dimethylaminoethyl)-5-hydroxyindole; 5-hydroxy-N,N-dimethyltryptamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| bumetanide | Bumex | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Bumetanide |
| buprenorphine | Buprenex; Temgesic; Subutex; Suboxone | DEA Controlled Substance List: Schedule III | OPSS entry |
| buserelin | tiloryth | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| butabarbital | Butisol; secbutabarbital; Butibel | DEA Controlled Substance List: Schedule III | OPSS entry |
| butalbital | Fiorinal; butalbital with aspirin | DEA Controlled Substance List: Schedule III | OPSS entry |
| butobarbital | Soneryl; butethal | DEA Controlled Substance List: Schedule III | OPSS entry |
| butonitazene | (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1- amine); 1H-benzimidazole-1-ethanamine, 2-((4-butoxyphenyl)methyl)-N,N-diethyl-5-nitro-; 2-[(4-butoxyphenyl)methyl]-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine; 2-[2-[(4-butoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]-N,N-diethylethanamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| butorphanol | (-)-17-(cyclobutylmethyl)morphinan-3,14-diol; Stadol; Torbugesic; Torbutrol; Stadol NS (+1) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| butylone | MDDMC; bk-MDDMA; N,N-dimethyl-3,4-methylenedioxycathinone; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| butyryl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide; N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| calusterone | Mesosarb; 7β,17α-dimethyltestosterone; 7beta,17alpha-dimethyl-17betahydroxyandrost-4-en-3-one; 7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| camazepam | Limpidon; Paxor; Albego | DEA Controlled Substance List: Schedule IV | OPSS entry |
| cannabidiol | CBD; Epidiolex; 1,3-benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-; delta1(2)-trans-cannabidiol; trans-cannabidiol (+3) | Military policy | Hemp and DoD policy |
| cannabigerol | cannabigerol (CBG); Cannabis Extract 5% CBG; CBG | DoDI 1010.16 | OPSS entry |
| cannabinol | 6,6,9-trimethyl-3-pentyl-benzo[c]chromen-1-ol; CBN | DoDI 1010.16 | OPSS entry |
| cannabis | Cannabis sativa L.; Cannabis sativa | DEA Controlled Substance List: Schedule I | OPSS entry |
| canrenone | Aldadiene | WADA S5: Diuretics and Masking Agents | OPSS entry |
| capromorelin | CP-424,391 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| carbamylated EPO | cEPO | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| carbazole | dibenzopyrrole; 9h-carbazole | DoDI 1010.16 | OPSS entry |
| carfentanil | Wildnil | DEA Controlled Substance List: Schedule III | OPSS entry |
| carisoprodol | Soma | DEA Controlled Substance List: Schedule IV | OPSS entry |
| Catha edulis | khat; Abyssinian tea; Graba | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| cathine | d-norpseudoephedrine; Fasupond; norpseudoephedrine; (+)-norpseudoephedrine; Exponcit (+1) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| cathinone | alpha-aminopropiophenone; 2-aminopropiophenone; 2-amino-1-phenyl-1-propanone; norephedrone | DEA Controlled Substance List: Schedule I | OPSS entry |
| cenobamate | carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester); 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate | DEA Controlled Substance List: Schedule V | OPSS entry |
| cesium chloride | cesium salt; CsCl; caesium chloride | FDA Statement | FDA: Cesium Chloride in Dietary Supplements |
| chloral betaine | Beta Chlor | DEA Controlled Substance List: Schedule IV | OPSS entry |
| chloral hydrate | Noctec | DEA Controlled Substance List: Schedule IV | OPSS entry |
| chlordiazepoxide | Libritabs; Librium; SK-Lygen; Limbitrol | DEA Controlled Substance List: Schedule IV | OPSS entry |
| chlorhexadol | Medodorm; Mecoral; Mechloral; Chloralodol | DEA Controlled Substance List: Schedule III | OPSS entry |
| chlorodehydromethylandrostenediol | H-DROL; halodrol; 4-chloro-17α-methyl-androsta-1,4-diene-3,17β-diol; 4-chloro-17a-methyl-androst-1,4-diene-3b,17b-diol; 4-chloro-17alpha-methyl-androst-1,4-diene-3beta,17beta-diol (+7) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| chloromethylandrostenediol | Promagnon; 4-chloro-17alpha-methyl-androst-4-ene-3beta,17beta-diol; 4-chloro-17α-methyl-androst-4-ene-3β,17β-diol; 4-chloro-17-methyl-androst-4-ene-3,17-diol; methyl-clostediol (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| chlorothiazide | Diuril | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Chlorothiazide |
| chlorphentermine | Desopimon; Apsedon; Pre-Sate; Lucofen | DEA Controlled Substance List: Schedule III | OPSS entry |
| chlorthalidone | chlortalidone | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Chlorthalidone |
| clenbuterol | Clen | WADA S1: Anabolic Agents | OPSS entry |
| clobazam | Urbanyl; Urbadan | DEA Controlled Substance List: Schedule IV | OPSS entry |
| clobenzorex | benzeneethanamine, N-((2-chlorophenyl)methyl)-α-methyl-, (S)-; (+)-N-(O-chlorobenzyl)-alpha-methylphenethylamine; benzeneethanamine, N-((2-chlorophenyl)methyl)-alpha-methyl-, (S)-; (+)-N-(O-chlorobenzyl)-α-methylphenethylamine | Unapproved Drug; DoDI 1010.16 | NIH NCATS Inxight Drugs entry: Clobenzorex |
| clomifene | clomifen; clomifenum; Serophene; 2-(4-(2-chloro-1,2-diphenylethenyl)phenoxy)-N,N-diethylethanamine; Klostilbegit (+19) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Clomiphene |
| clonazepam | klonopin; clonopin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| clonitazene | benzimidazole, 2-(p-chlorobenzyl)-1-(2-(diethylamino)ethyl)-5-nitro-; clobedolum; 2-(p-chlorobenzyl)-1-(2-diethylaminoethyl)-5-nitrobenzimidazole | DEA Controlled Substance List: Schedule I | OPSS entry |
| clorazepate | Tranxene | DEA Controlled Substance List: Schedule IV | OPSS entry |
| clortermine | Voranil | DEA Controlled Substance List: Schedule III | OPSS entry |
| clostebol | clostebol acetate; 4-chlorotestosterone; Alfa-Trofodermin; 4-chloro-17beta-hydroxyandrost-4-en-3-one; 4-chloro-Δ4-androstene-3α-ol-17-one (+3) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| clotiazepam | Trecalmo; Rize; Veratran; Clozan | DEA Controlled Substance List: Schedule IV | OPSS entry |
| cloxazolam | Akton; Olcadil; Luballix; Sepazon | DEA Controlled Substance List: Schedule IV | OPSS entry |
| CNTO-530 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| cobalt | cobalt chloride | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| cocaine | coca leaves; methyl benzoylecgonine; Crack | DEA Controlled Substance List: Schedule II | OPSS entry |
| cocaine metabolites | DoDI 1010.16 | OPSS entry | |
| codeine | morphine methyl ester; methyl morphine | DEA Controlled Substance List: Schedule II | OPSS entry |
| codeine methylbromide | codeine bromomethylate; Eucodin; codeine methyl bromide | DEA Controlled Substance List: Schedule I | OPSS entry |
| codeine-N-oxide | codeine N-oxide | DEA Controlled Substance List: Schedule I | OPSS entry |
| coluracetam | N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-B)quinolin-4-YL)-2-(2-oxopyrrolidin-1-YL)acetamide | FDA Statement | FDA Statement |
| conivaptan | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Conivaptan | |
| corticorelin | corticorelin acetate | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| CP-47,497 | 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol; 5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol; CP-47,497 C8 Homologue | DEA Controlled Substance List: Schedule I | OPSS entry |
| crotonyl fentanyl | (E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| CUMYL-4CN-BINACA | 4-cyano-CUMYL-BUTINACA; 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; 4-CN-CUMYL BINACA; SGT-78; 4-CN-CUMYL-BUTINACA | DEA Controlled Substance List: Schedule I | OPSS entry |
| CUMYL-PEGACLONE | 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-B]indole-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| cyanostane | 2-cyano-17a-methyl-17b-hydroxy androst-3-one; 2-cyano-17a-methyl-17b-hydroxy-5a-androst-3-one; 2-cyano-17a-methyl-17b-hydroxy-androstan-3-one | WADA S1: Anabolic Agents | OPSS entry |
| cyclofenil | Sexovid; NSC 86464; cyclophenyl; cyclophenil; Neoclym (+23) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| cyclopentyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| cyclopropyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| cyprenorphine | N-Cyclopropylmethyl-6,14-endoetheno-7alpha-(1-hydroxy-1-methylethyl)-6,7,8,14-tetrahydronororipavine; 6,14-endo-Ethenotetrahydrooripavine, 21-cyclopropyl-7alpha-(1-hydroxy-1-methylethyl)-; 2-(N-cyclopropylmethyl-4,5-epoxy-6-methoxy-6,14-endo-morphinan-7alpha-yl)-2-propanol | DEA Controlled Substance List: Schedule I | OPSS entry |
| cyproheptadine | Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-; 1-Methyl-4-(dibenzo[a,e]cycloheptatrien-5-ylidene)piperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; Periactinol; Periactin (+2) | Prescription drug | NIH NCATS Inxight Drugs entry: Cyproheptadine |
| danazol | [1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol; Danocrine; Danol | WADA S1: Anabolic Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Danazol |
| dapoxetine | FDA Statement | FDA: Public Notification | |
| daprodustat | GSK1278863 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| darbepoetin alfa | Aranesp; darbepoetin | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Darbepoetin alfa |
| daridorexant | methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-; Nemorexant; Quviviq; [(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone; [(2~{S})-2-(6-chloranyl-7-methyl-1~{H}-benzimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-[5-methoxy-2-(1,2,3-triazol-2-yl)phenyl]methanone (+5) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| dehydrochlormethyltestosterone | dehydrochloromethyltestosterone; oral-turinabol; turinabol-oral; 4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one; oral turinabol (+4) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| dehydroepiandrosterone | 5-androsten-3-beta-hydroxy-17-one; 3b-hydroxy-androst-5-ene-17-one; 3beta-hydroxy-androst-5-ene-17-one; trans-dehydroandrosterone; Prasterone, 3 alpha Isomer (+18) | WADA S1: Anabolic Agents; Military policy | DoDI 6130.06 Use of Dietary Supplements in the DoD |
| delorazepam | chlordesmethyldiazepam; nordiclazepam | DEA Controlled Substance List: Schedule IV | OPSS entry |
| demelverine | N-methyl-β,β′-diphenyldiethylamine; N-methyl-N-(2-phenylethyl)benzeneethanamine; N-methylbis(2-phenylethyl)amine; N-methyl-N-phenethyl-2-phenylethanamine; diphenethylamine, N-methyl- (+7) | Military policy | DoDI 6130.06 Use of Dietary Supplements in the DoD |
| des(1-3)IGF-1 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| Desidustat | ZYAN1 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry |
| deslorelin | D-TRP-LHRH-PEA | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| desmopressin | DDAVP; Stimate; Nocdurna | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Desmopressin |
| desomorphine | 6-deoxy-7,8-dihydromorphine; dihydrodesoxymorphine-D; 4,5-epoxy-3-hydroxy-N-methylmorphinan; Permonid; crocodile (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| desoxymethyltestosterone | Pheraplex; 17α-methyl-5α-androst-2-en-17β-ol; 17α-methyl-5α-androst-3-en-17β-ol; madol; 17alpha-methyl-5alpha-androst-2-en-17beta-ol (+1) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| desoxytestosterone | 5α-androst-2-en-17β-ol; 5α-androst-3-en-17β-ol | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| dextromoramide | Jetrium; Palfium; Narcolo | DEA Controlled Substance List: Schedule I | OPSS entry |
| dextropropoxyphene | propoxyphene; Darvon; alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; Darvocet; Propacet | DEA Controlled Substance List: Schedule II; DEA Controlled Substance List: Schedule IV | OPSS entry |
| diampromide | N-[2-(methylphenethylamino)propyl]propionanilide; propionanilide, N-(2-(methylphenethylamino)propyl)- | DEA Controlled Substance List: Schedule I | OPSS entry |
| diazepam | Valium; Diastat | DEA Controlled Substance List: Schedule IV | OPSS entry |
| dichloralphenazone | dichloralantipyrine; Midrin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| dienolone | estra-4,9-dien-17b-ol-3-one; dienalone; 3-oxo-4,9-estradien-17β-ol; RU 3118; 17β-Hydroxy-estra-4,9-dien-3-one (+3) | WADA S1: Anabolic Agents | OPSS entry |
| diethylpropion | diethylpropione; Danylen; amfepramon; amphepramone; Derfon (+14) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| diethylthiambutene | DEA Controlled Substance List: Schedule I | OPSS entry | |
| diethyltryptamine | DET; MiPT; N,N-diethyltryptamine; N-methyl-N-isopropyltryptamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| difenoxin | Lyspafen; Motofen | DEA Controlled Substance List: Schedule I | OPSS entry |
| dihexa | N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; L-Isoleucinamide, N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-; PNB-0408 | FDA Statement | FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks |
| dihydrocodeine | Parzone; Didrate | DEA Controlled Substance List: Schedule II | OPSS entry |
| dihydroetorphine | tetrahydro-7alpha-(1-hydroxy-1-methylbutyl)-6,14-endo-ethanooripavine; DHE; 7,8-dihydro-7alpha-(1-(R)-hydroxy-1-methylbutyl)-6,14-endo-ethanotetrahydrooripavine; 18,19-dihydroetorphine | DEA Controlled Substance List: Schedule II | OPSS entry |
| dihydromorphine | 7,8 dihydromorphine; Paramorphan; 6-alpha-hydromorphol; hydromorphine; 7,8-dihydromorphine | DEA Controlled Substance List: Schedule I | OPSS entry |
| dimenoxadol | Lokarin; 2-(dimethylamino)ethyl ethoxydiphenylacetate; dimenoxadole; 2-(dimethylamino)ethyl 2-ethoxy-2,2-diphenylacetate; Estocine | DEA Controlled Substance List: Schedule I | OPSS entry |
| dimepheptanol | methadol; racemethadol | DEA Controlled Substance List: Schedule I | OPSS entry |
| dimethandrolone | 7alpha,11beta-dimethyl-19-nortestosterone; 7α,11β-dimethyl-19-nortestosterone | WADA S1: Anabolic Agents | OPSS entry |
| dimethoxymethamphetamine | 3,4-dimethoxymethamphetamine; DMMA | DoDI 1010.16 | OPSS entry |
| dimethylthiambutene | dimethibutin; aminobutene; 3-dimethylamino-1,1-bis(2-thienyl)-1-butene; N,N,1-trimethyl-3,3-di-2-thienylallylamine; Ohton | DEA Controlled Substance List: Schedule I | OPSS entry |
| dimethyltrienolone | 17β-Hydroxy-7α,17α-dimethyl-estra-4,9,11-trien-3-one; 17beta-hydroxy-7alpha,17alpha-dimethyl-estra-4,9,11-trien-3-one; RU-2420 | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| dimethyltryptamine | DMT; N,N-dimethyltryptamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| dinitrophenol | 2.4-dinitrophenol; Dinosan; Nitrophen; Mitcal; DNP (+6) | WADA S0: Non-approved Substances | OPSS entry |
| dioxaphetyl butyrate | ethyl 4-morpholino-2,2-diphenylbutyrate; 4-morpholinebutanoic acid, alpha,alpha-diphenyl-, ethyl ester; Amidalgon; Spasmoxal | DEA Controlled Substance List: Schedule I | OPSS entry |
| diphenoxylate | DEA Controlled Substance List: Schedule II | OPSS entry | |
| dipipanone | phenylpiperone HCl; Wellconal; Dipipan; Diconal | DEA Controlled Substance List: Schedule I | OPSS entry |
| DiPT | N,N-diisopropyltryptamine | Other reason | DoDI 1010.04 Problematic Substance Use by DoD Personnel |
| DMAA (1,3) | 1,3-DMAA; dimethylpentylamine; Floradrene; 1,3-dimethylpentylamine; methylhexanamine (+12) | FDA Statement | FDA: DMAA in Dietary Supplements |
| DMAA (1,4) | 5-methyl-2-hexylamine; 5-methylhexan-2-amine; 1,4 dimethylamylamine; 1,4-DMAA; DMPA (+2) | FDA Warning Letter | FDA Warning Letter |
| DMBA | 1,3-DMBA; 1,3-dimethylbutanamine; 4-methyl-2-pentanamine; 4-amino-2-methylpentane citrate; 4-amino-2-pentanamine (+14) | FDA Statement | FDA: DMBA in Dietary Supplements |
| DMHA | Vaporpac; 1,5-DMHA; 2-isooctyl amine; 2-aminoisoheptane HCl (DMHA); 6-methyl-2-heptylamine (+16) | FDA Statement | FDA: DMHA in Dietary Supplements |
| DOB | 4-bromo-2,5-dimethoxyamphetamine; 4-bromo-DMA | DEA Controlled Substance List: Schedule I | OPSS entry |
| DOC | 2,5-dimethoxy-4-chloroamphetamine | DoDI 1010.16 | OPSS entry |
| DOET | 2,5-dimethoxy-4-ethylamphetamine; 2,5-dimethoxy-4-ethylamphet-amine | DEA Controlled Substance List: Schedule I | OPSS entry |
| DOI | 2,5-dimethoxy-4-iodoamphetamine | DoDI 1010.16 | OPSS entry |
| DOM | STP; 4-methyl-2,5-dimethoxy-α-methylphenethylamine; 2C-G; 4-methyl-2,5-dimethoxy-amphetamine; 2,5-Dimethoxy-3,4-dimethylphenethylamine (+1) | DEA Controlled Substance List: Schedule I | OPSS entry |
| domagrozumab | PF-06252616 | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| dronabinol | (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo [b,d]pyran-1-ol; (-)-delta-9-(trans)-tetrahydrocannabinol; Syndros; Marinol; (-)-delta-9-trans tetrahydrocannabinol | DEA Controlled Substance List: Schedule II | OPSS entry |
| drostanolone | Masteron; Masterone; Drolban; 17beta-hydroxy-2alpha-methyl-5alphaandrostan-3-one; Masteril (+6) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| drotebanol | oxymethebanol; Metabanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| ecgonine | cocaine precursor | DEA Controlled Substance List: Schedule II | OPSS entry |
| ecgonine methyl ester | EME; methylecgonine | DoDI 1010.16 | OPSS entry |
| elacestrant | WADA S4: Hormone and Metabolic Modulators | OPSS entry | |
| eluxadoline | VIBERZI; 5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid | DEA Controlled Substance List: Schedule IV | OPSS entry |
| embutramide | Tributane | DEA Controlled Substance List: Schedule III | OPSS entry |
| Enarodustat | JTZ-951 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry |
| enobosarm | MK2866 acetic acid ester; GTx-024; GTx 024; Ostarine; S22 (+16) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| ephedra | epitonin; Sida cordifolia Linn; Ephedra intermedia; heart-leaf sida; Pinellia ternata (+6) | Other reason | Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk |
| ephedrine alkaloids | norephedrine; ephedrine; ephedra alkaloids; N-pseudoephedrine | Other reason | Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk |
| epi-dihydrotestosterone | 5beta-DHT; 5beta-dihydrotestosterone; 17beta-hydroxyetiocholan-3-one; 17β-hydroxy-5β-androstan-3-one; etiocholan-17β-ol-3-on (+7) | WADA S1: Anabolic Agents | OPSS entry |
| epiandrosterone | trans-androsterone; 3beta-hydroxy-5alpha-androstan-17-one; 3b-hydroxy-5a-androstan-17-one; epiandrosterone (from pine pollen); epiandrostenolone (+14) | WADA S1: Anabolic Agents | OPSS entry |
| epistane | havoc; 2α,3α-Epithio-5α-androstan-17α-methyl-17β-ol; epitiostanol; 2,3-thioepoxy madol; epi plex (+7) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| epitalon | FDA Statement | FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | |
| epitestosterone | 17alpha-testosterone; 17alpha-hydroxyandrost-4-en-3-one; 17α-testosterone; cis-testosterone; isotestosterone (+5) | WADA S1: Anabolic Agents | OPSS entry |
| epitrenbolone | α-trenbolone; 17alpha-hydroxytrenbolone; estra-4,9,11-trien-3-one, 17-hydroxy-, (17-alpha)-; 17alpha-trenbolone; 17α-trenbolone (+4) | WADA S1: Anabolic Agents | OPSS entry |
| epthiostane | 17β-hydroxy-2α,3α-epithio-5α-androstane | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| erythropoietin | rEPO; epoetin alfa; epoetin epsilon; EPO; epoetin kappa (+10) | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Erythropoietin |
| erythropoietin Fc | EPO-Fc | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| estazolam | Eurodin; Domnamid; Nuctalon; ProSom | DEA Controlled Substance List: Schedule IV | OPSS entry |
| estra-4,9,11-triene-3,17-dione | trenavar; trendione | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| ethacrynic acid | etacrynic acid; sodium ethacrynate; ethacrinic acid | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Ethacrynic acid |
| ethchlorvynol | Placidyl | DEA Controlled Substance List: Schedule IV | OPSS entry |
| ethinamate | Valmid; Valamin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| ethyl loflazepate | Meilax; Ronlax; Victan; ethyl 7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-OXO-1H-1,4-benzodiazepine-3-carboxylate; CM 6912 | DEA Controlled Substance List: Schedule IV | OPSS entry |
| ethylestrenol | 17alpha-ethyl-17beta-hydroxyestr-4-ene; 17α-ethyl-17β-hydroxyestr-4-ene; Orabolin; 19-norpregna-4-en-17α-ol; 19-norpregna-4-en-17ɑ-ol (+3) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| ethylmethylthiambutene | DEA Controlled Substance List: Schedule I | OPSS entry | |
| ethylmorphine | Dionin | DEA Controlled Substance List: Schedule II | OPSS entry |
| ethylone | MDEC; 3,4-methylenedioxy-N-ethylcathinone; bk-MDEA; βk-MDEA; 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| ethylphenidate | EPH; ethylphenidate, threo- | DEA Controlled Substance List: Schedule I | OPSS entry |
| etiocholanolone | 3alpha-hydroxy-5beta-androstan-17-one; 5-isoandrosterone; 3α-hydroxy-5β-androstan-17-one | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| etodesnitazene | Etazone; benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-ethoxybenzyl)-; 1H-benzimidazole-1-ethanamine, 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-; 2-(2-(4-ethoxybenzyl)-1Hbenzimadazol-1-yl)-N,N-diethylethan-1-amine; 2-((4-ethoxyphenyl)methyl)-N,N-diethyl-1H-benzimidazole-1-ethanamine (+4) | DEA Controlled Substance List: Schedule I | OPSS entry |
| etonitazene | Chinese Dwarf; 1-(2-(diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitrobenzimidazole; etonitazine | DEA Controlled Substance List: Schedule I | OPSS entry |
| etorphine hydrochloride | M 99; etorphine HCl | DEA Controlled Substance List: Schedule II | OPSS entry |
| etoxeridine | Wy-2039; Carbetidine; Atenos; isonipecotic acid, 1-(2-(2-hydroxyethoxy)ethyl)-4-phenyl-, ethyl ester; ethyl 1-[2-(2-hydroxyethoxy)ethyl]-4-phenylpiperidine-4-carboxylate | DEA Controlled Substance List: Schedule I | OPSS entry |
| eutylone | 1-(1,3-benzodioxol-5-yl)-2(ethylamino)butan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| examorelin | hexarelin | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| exemestane | Aromasin; PNU-155971; 6-methylenandrosta-1,4-diene-3,17-dione; exemestano; FCE-24304 (+10) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Exemestane |
| ezogabine | Potiga; N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester | DEA Controlled Substance List: Schedule V | OPSS entry |
| fencamfamin | Reactivan | DEA Controlled Substance List: Schedule IV | OPSS entry |
| fencamine | Sicoclor; 1,3,7-trimethyl-8-[2-[methyl(1-phenylpropan-2-yl)amino]ethylamino]purine-2,6-dione; Altimina | DoDI 1010.16 | OPSS entry |
| fenethylline | amfetyline; ethyltheophylline amphetamine; fenetylline; Captagon | DEA Controlled Substance List: Schedule I | OPSS entry |
| fenoterol | (1RS)-1-(3,5-dihydroxyphenyl)-2-(((1RS)-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethanol; 3,5-dihydroxy-alpha-(((P-hydroxy-alpha-methylphenethyl)amino)methyl)benzyl alcohol; 3,5-dihydroxy-α-(((P-hydroxy-α-methylphenethyl)amino)methyl)benzyl alcohol; 1,3-benzenediol, 5-(1-hydroxy-2-((2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)- | WADA S3: Beta-2 Agonists | OPSS entry |
| fenproporex | Solvolip; Gacilin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| fentanyl | Actiq; Innovar; Duragesic; Oralet; Sublimaze | DEA Controlled Substance List: Schedule II | OPSS entry |
| fentanyl carbamate | ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate | DEA Controlled Substance List: Schedule I | OPSS entry |
| fludiazepam | DEA Controlled Substance List: Schedule IV | OPSS entry | |
| flunitazene | 1H-benzimidazole-1-ethanamine, N,N-diethyl-2-((4-fluorophenyl)methyl)-5-nitro-; benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-fluorobenzyl)-5-nitro-; N,N-diethyl-2-((4-fluorophenyl)methyl)-5-nitro-1H-benzimidazole-1-ethanamine; N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine | DEA Controlled Substance List: Schedule I | OPSS entry |
| flunitrazepam | Roipnol; Rohypnol; Narcozep; Darkene | DEA Controlled Substance List: Schedule IV | OPSS entry |
| fluoxymesterone | Halotestin; Ora-Testryl; Stenox; 9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one; 9α-Fluoro-11β,17β-dihydroxy-17α-methylandrost-4-en-3-one (+3) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| flurazepam | Dalmane | DEA Controlled Substance List: Schedule IV | OPSS entry |
| follistatin | activin-binding protein; FST | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| fonturacetam | phenylpiracetam; carphedon; Karfedon; Carphedone; 4-phenylpiracetam (+1) | FDA Statement | FDA Statement |
| formebolone | 2-Formyl-17α-methyl-1,4-androsta-1,4-dien-11α,17β-diol-3- one; Esiclene; 2-formyl-17alpha-methyl-11alpha,17beta-dihydroxyandrost-1,4-dien-3-one; 2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one; Hubernol | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| formestane | 4-hydroxy-delta(sub 4)-androstenedione; 4-hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5alpha-androstan-17beta-ol; BRN 1889793; 4-hydroxy-androst-4-ene-3,17-dione; 4-hydroxyandrost-4-ene-3,17-dione (+13) | DEA Controlled Substance List: Schedule III; WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| formoterol | eformoterol; Turbuhaler®; Oxis®; formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)- | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Formoterol |
| fospropofol | Lusedra | DEA Controlled Substance List: Schedule IV | OPSS entry |
| FP-3 | Pentobarbital & noncontrolled active ingred | DEA Controlled Substance List: Schedule III | OPSS entry |
| FUB-144 | [1-[(4-Fluorophenyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; FUB-UR-144; (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone; Methanone, [1-[(4-fluorophenyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-; (1-(4-Fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone | DEA Controlled Substance List: Schedule I | OPSS entry |
| FUB-APINACA | AKB48 N-(4-FLUOROBENZYL); FUB-AKB48; N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamid | DEA Controlled Substance List: Schedule I | OPSS entry |
| fulvestrant | ICI 182,780; Faslodex; ICI-182780; ICI 182780; ZM182780 (+4) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Fulvestrant |
| furanyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| furazabol | Frazalon; 17alpha-methyl-17beta-hydroxyandrostano[2,3-c]-furazan; Miotolon; 17ɑ-methyl [1,2,5] oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol; Furuza (+5) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| furethidine | 1-(2-tetrahydrofurfuryloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester; ethyl 4-phenyl-1-(2-tetrahydrofurfuryloxyethyl)piperidine-4-carboxylate | DEA Controlled Substance List: Schedule I | OPSS entry |
| furfenorex | furfurylmethylamphetamine | Unapproved Drug; DoDI 1010.16 | NIH NCATS Inxight Drugs entry: Furfenorex |
| furosemide | Lasix | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Furosemide |
| galantamine | Razadyne ER; Razadyne; Galantamine HBr; Galantamine hydrobromide | Prescription drug; FDA Warning Letter | FDA Warning Letter |
| gamma hydroxybutyric acid | Anetamin; 4-hydroxybutanoic acid; gamma-hydroxybutyric acid; GHB; 4-hydroxybutyrate (+6) | DEA Controlled Substance List: Schedule I | OPSS entry |
| gamma-butyrolactone | gamma butyrolactone; GBL; 4-butyrolactone | DEA Controlled Substance List: Schedule I | OPSS entry |
| ganaxolone | 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one; 1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-Hydroxy-3,10,13-trimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone; 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one; (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one (+3) | DEA Controlled Substance List: Schedule V | OPSS entry |
| gestrinone | (17alpha)-13-ethyl-17-hydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one; dimetriose; (17α)-13-ethyl-17-hydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one; 13-Ethyl-17a-ethynyl-17b-hydroxygona-4,9,11-trien-3-one; 13β-Ethyl-17β-hydroxy-18,19-dinor-17α-pregna-4,9,11-trien- 20-yn-3-one (+3) | WADA S1: Anabolic Agents | OPSS entry |
| GHRP-1 | GHRP1; growth hormone-releasing peptide 1 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| GHRP-6 | growth hormone-releasing peptide hexapeptide; hexapeptide-2; growth hormone-releasing peptide 6 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| glutethimide | Doriden; Dorimide | DEA Controlled Substance List: Schedule II | OPSS entry |
| gonadorelin | gonadotropin-releasing hormone; LHRH; luteinizing hormone-releasing factor; gonadorelin decapeptide; GNRH | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| goralatide | Seraspenide; Ac-SDKP | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| goserelin | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Goserelin | |
| growth hormone-releasing peptide | GHRP; GHRP-5; GHRP-3; GHRP-4; GH-releasing peptides | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| GSK2881078 | SARM GSK2881078 | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| GW-0742 | 2-(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methyl)thio)-2-methylphenoxy)acetic acid; GW610742; GW-0742X; GWδ 0742; GW0742 (+9) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| GW-501516 | Cardarine; GW501516; 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]- 1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid; GSK-516; GW-1516 (+4) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| halazepam | Paxipam | DEA Controlled Substance List: Schedule IV | OPSS entry |
| haloxazolam | Haloxazolamum; Somelin; 10-bromo-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydrooxazolo(3,2-d)(1,4)benzodiazepin-6(5H)-one | DEA Controlled Substance List: Schedule IV | OPSS entry |
| HCG | hCG; chorionic gonadotrophin (CG); human chorionic gonadotropin; chorionic gonadotropin; chorionic gonadotrophin | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Chorionic gonadotropin |
| hemp | hemp seed protein powder; organic hemp protein concentrate; hemp seed protein; organic hemp protein powder ; hemp seed (+5) | Military policy | 26 February 2020 Memorandum from the Office of Under Secretary of Defense |
| heroin | diacetylmorphine; diamorphine hydrochloride; diamorphine | DEA Controlled Substance List: Schedule I | OPSS entry |
| hexadrone | 6-chloro-androst-4-ene-3-one-17beta-ol; 6-chloro-androst-4-ene-3-one-17β-ol; 6-chloro-androst-4-en-17b-ol-3-one | WADA S1: Anabolic Agents; FDA Warning Letter | FDA Warning Letter |
| hexedrone | alpha-methylamino-caprophenone; 2-(methylamino)-1-phenyl-1-hexanone; α-methylamino-caprophenone; 1-hexanone, 2-(methylamino)-1-phenyl- | DoDI 1010.16 | OPSS entry |
| HGH | Nutropin AQ; human growth hormone; Genotonorm; Nutropin Depot; Accretropin (+22) | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Somatropin |
| higenamine | 6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((4-hydroxyphenyl)methyl)-, (+-)-; (R)-higenamine; (R,S)-norcoclaurine; (+-)-demethylcoclaurine; higenamine hydrochloride (+18) | WADA S3: Beta-2 Agonists; FDA Warning Letter | FDA Warning Letter |
| histrelin | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Histrelin | |
| hordenine | anhaline; p-hydroxy-N,N-dimethylphenethylamine; eremursine; ordenina; peyocactine (+8) | FDA Warning Letter | FDA warning letter |
| hydrochlorothiazide | Microzide; HCTZ | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Hydrochlorothiazide |
| hydrocodone | dihydrocodeinone | DEA Controlled Substance List: Schedule II | OPSS entry |
| hydromorphinol | 14-hydroxydihydromorphine; 7,8-dihydro-14-hydroxymorphine; RAM-320; 6alpha-Oxymorphol | DEA Controlled Substance List: Schedule I | OPSS entry |
| hydromorphone | Dilaudid; dihydromorphinone | DEA Controlled Substance List: Schedule II | OPSS entry |
| hydroxyamphetamine | hydroxyamfetamine; parahydroxyamphetamine | DoDI 1010.16 | OPSS entry |
| hydroxypethidine | Demidone; Oxydolantin; ethyl 4-(3-hydroxyphenyl)-1-methylpiperidine-4-carboxylate; Oxipethidine; Oxypetidin (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| hydroxypropyl betadex | hydroxypropyl-β-cyclodextrin; hydroxypropyl-B-cyclodextrin; HP-β-CD; hydroxypropyl beta cyclodextrin; beta-hydroxypropylcyclodextrin (+14) | Unapproved Drug | FDA Designated Orphan Drug |
| ibogaine | 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga | DEA Controlled Substance List: Schedule I | OPSS entry |
| IGF | Mecasermin; Somatomedin C; recombinant human insulin-like growth factor-1; IGF-1; insulin-like growth factor 1 | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Mecasermin |
| indacaterol | Onbrez; QAB-149 | WADA S3: Beta-2 Agonists; Discontinued drug | NIH NCATS Inxight Drugs entry: Indicaterol |
| indapamide | Lozol | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Indapamide |
| indene | 1H-indene | DoDI 1010.16 | OPSS entry |
| IOX2 | JICL38 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| IOX4 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| ipamorelin | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| isobutyryl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| isomethadone | isomethadone II; Win 1783; 1,1-diphenyl-1-(dimethylaminoisopropyl)butanone-2; isoamidone; isoamidone II (+1) | DEA Controlled Substance List: Schedule II; DoDI 1010.16 | OPSS entry |
| isometheptene | isonyl; octanil; octinum; 5-hepten-2-amine, N,6-dimethyl-; octin | FDA Statement | FDA Statement |
| isopropylnorsynephrine | Deterenol; isopropyloctopamine; N-isopropyloctopamine; Betaphrine; N-isopropylnorsynephrine | Unapproved Drug; FDA Statement | FDA: New dietary ingredient response letter |
| isotonitazene | N,N-diethyl-2-(2-(4 isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine; N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| isovaleryl fentanyl | Isovalerylfentanyl; 3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide; isovalery fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| JNJ-28330835 | JNJ 28330835; (3 S)-3-methyl-5-trifluoromethyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid N-(4-cyano-3-trifluoromethylphenyl)amide); 1H-pyrazole-5-carboxamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-4,5-dihydro-5-methyl-3-(trifluoromethyl)-, (5S)-; (S)-3-methyl-5-trifluoromethyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid N-(4-cyano-3-trifluoromethylphenyl)amide) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| ketamine | Ketaset; Special K; Ketalar; K; (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone | DEA Controlled Substance List: Schedule III | OPSS entry |
| ketazolam | Contamex; Loftran; Solatran; Anxon | DEA Controlled Substance List: Schedule IV | OPSS entry |
| ketobemidone | Cliradon | DEA Controlled Substance List: Schedule I | OPSS entry |
| kisspeptin | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| kratom | ithang; kakuam; madat; mambog; cratom (+25) | Military policy; FDA Statement | ALNAV 003/26 |
| lacosamide | (R)-2-acetoamido-N-benzyl-3-methoxy-propionamide; Vimpat | DEA Controlled Substance List: Schedule V | OPSS entry |
| landogrozumab | anti-myostatin antibody | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| lasmiditan | Reyvow; 2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide | DEA Controlled Substance List: Schedule V | OPSS entry |
| lefetamine | (-)-1-dimethylamino-1,2-diphenylethane; SPA; 1-dimethylamino-1,2-diphenylethane | DEA Controlled Substance List: Schedule IV | OPSS entry |
| lemborexant | (1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide | DEA Controlled Substance List: Schedule IV | OPSS entry |
| lenomorelin | ghrelin; ghrelin human | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| letrozole | 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile); HSDB 7461; CGS20267; CCRIS 8822; 4-[(4-Cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile (+5) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Letrozole |
| leuprorelin | leuprolide | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Leuprolide |
| levo-alphacetylmethadol | LAAM; levo-alpha-acetylmethadol; levomethadyl acetate | DEA Controlled Substance List: Schedule II | OPSS entry |
| levomethamphetamine | levmetamfetamine; l-methamphetamine | DoDI 1010.16; OTC drug | NIH NCATS Inxight Drugs entry: Levmetamfetamine |
| levomethorphan | methorphan; l-methorphan | DEA Controlled Substance List: Schedule II | OPSS entry |
| levomoramide | levoramide; (3R)-3-methyl-4-morpholin-4-yl-2,2-diphenyl-1-pyrrolidin-1-ylbutan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| levophenacylmorphan | (-)-3-hydroxy-N-phenacylmorphinan; benzorphanol | DEA Controlled Substance List: Schedule I | OPSS entry |
| levorphanol | Levo-Dromoran | DEA Controlled Substance List: Schedule II | OPSS entry |
| levosalbutamol | levalbuterol | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Levalbuterol |
| LGD-2226 | 6-(bis-(2,2,2-trifluoroethyl)amino)-4-trifluoromethyl-1H-quinolin-2-one; LGD2226 | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| LGD-3303 | LGD3303; 7H-pyrrolo(3,2-F)quinolin-7-one, 9-chloro-2-ethyl-3,6-dihydro-1-methyl-3-(2,2,2-trifluoroethyl)-; LGD-3033; 9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one; LGD 3033 (+1) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| LGD-4033 | 4-[(2R)-w-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile; 4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-(trifluoromethyl)benzonitrile; Ligandrol; anabolicum; LGD4033 (+2) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| lisdexamfetamine | Vyvanse | DEA Controlled Substance List: Schedule II | OPSS entry |
| lonapegsomatropin | Skytrofa; lonapegsomatropin-tcgd; TRANSCONPEG HGH | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Lonapegsomatropin |
| long R3-IGF-1 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| loprazolam | DEA Controlled Substance List: Schedule IV | OPSS entry | |
| lorazepam | Ativan | DEA Controlled Substance List: Schedule IV | OPSS entry |
| lorcaserin | Belviq | DEA Controlled Substance List: Schedule IV | OPSS entry |
| lormetazepam | Noctamid | DEA Controlled Substance List: Schedule IV | OPSS entry |
| luspatercept | Reblozyl | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Luspatercept |
| luteinizing hormone | LH; luteinising hormone | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| lysergic acid | D-lysergic acid; (8R)-9,10-didehydro-6-methylergoline-8-carboxylic acid; ergoline acid | DEA Controlled Substance List: Schedule III | OPSS entry |
| lysergic acid amide | D-lysergic acid amide; lysergamide; ergine | DEA Controlled Substance List: Schedule III | OPSS entry |
| lysergic acid diethylamide | lysergide; LSD | DEA Controlled Substance List: Schedule I | OPSS entry |
| m-hydroxybenzoylecgonine | mOHBE; 3-hydroxybenzoylecgonine | DoDI 1010.16 | OPSS entry |
| m-hydroxycocaine | 3'-hydroxybenzoylecgonine methyl ester; 3'-hydroxycocaine | DoDI 1010.16 | OPSS entry |
| MAB-CHMINACA | ADB-CHMINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| macimorelin | WADA S2: Peptide Hormones, Growth Factors, etc.; Discontinued drug | NIH NCATS Inxight Drugs entry: Macimorelin | |
| marihuana | weed; marijuana; marihuana extract | DEA Controlled Substance List: Schedule I | OPSS entry |
| mazindol | Mazanor; Sanorex | DEA Controlled Substance List: Schedule IV | OPSS entry |
| MDA | N-hydroxy-3,4-methylenedioxyamphetamine; Love Drug; tenamfetamine; methylenedioxyamphetamine; 3,4-methylenedioxy amphetamine (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDEA | MDMB; 3,4-methylenedioxy-N-ethylamphetamine; MDE; N-ethyl MDA; N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDMA | Ectasy; 3,4-methylenedioxymethamphetamine; XTC; methylenedioxymethamphetamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDMB-4en-PINACA | methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDMB-CHMICA | methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; MMB-CHMINACA; MDMB–CHMICA; MMB–CHMINACA | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDMB-FUBINACA | methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; MDMB–FUBINACA | DEA Controlled Substance List: Schedule I | OPSS entry |
| MDPV | 3,4-methylenedioxypyrovalerone; 1-(1,3-benzodioxol-4-yl)-2-(pyrrolidin-1-yl)pentan-1-one (2,3-methylenedioxy pyrovalerone); 1-(1,3-benzodioxol-5-yl)-2-(cyclohexylamino)propan-1-one(n-cyclohexylmethylone); 3,4-methylenedioxy-α-cyclohexylaminopropiophenone | DEA Controlled Substance List: Schedule I | OPSS entry |
| mebolazine | 17-beta-hydroxy-2alpha,17-dimethyl-5-alpha-androstan-3-one azine; mebulazina; dimetazin; 17-β-hydroxy-2-α,17-dimethyl-5-α-androstan-3-one azine; Dostalon (+13) | WADA S1: Anabolic Agents; FDA Warning Letter | FDA Warning Letter |
| mebutamate | Capla | DEA Controlled Substance List: Schedule IV | OPSS entry |
| meclofenoxate | Analux; meclophenoxate; Proseryl; Cetrexin; Lucidril (+4) | Unapproved Drug | NIH NCATS Inxight Drugs entry: Meclofenoxate |
| mecloqualone | Nubarene | DEA Controlled Substance List: Schedule I | OPSS entry |
| medazepam | Nobrium | DEA Controlled Substance List: Schedule IV | OPSS entry |
| mefenorex | Doracil; Amexate; Anorexic; Pondinil | DEA Controlled Substance List: Schedule IV | OPSS entry |
| meldonium | MET-88; Q-4224-IOS; mildronate; 2-(2-carboxyethyl)-1,1,1-trimethyl hydrazinium hydroxide inner salt; mildronat (+11) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| mentabolan | (7alpha)-7-methylestr-4-ene-3,17-dione; 7alpha-methyl-estra-4-en-3,17-dione; 7α-methyl-estra-4-en-3,17-dione; 7α-methylestr-4-ene-3,17-dione; (7α,14β)-7-methylestra-4-ene-3,17-dione (+14) | FDA Warning Letter | FDA Warning Letter |
| mephedrone | Mcat; buphedrone; N,N-dimethyl-cathinone; 3-methyl-methcathinone; 4-methylmethcathinone (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| mephentermine | mephenterdrinum; mephentermine sulfate; mefentermina; mefenterdrin; Wyfentermina (+5) | Unapproved Drug | NIH NCATS Inxight Drugs entry: Mephentermine |
| meprobamate | Meprospan; Miltown; Micrainin; Equanil; Equagesic | DEA Controlled Substance List: Schedule IV | OPSS entry |
| mescaline | 3,4,5-trimethoxyphenethylamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| mesocarb | N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate | DEA Controlled Substance List: Schedule I | OPSS entry |
| mestanolone | 17a-methyl-d1-dihydrotestosterone; Tantarone; 17α-methyl-17β-hydroxy-5α-androstan-3-one; Methybol; 17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| mesterolone | 1α-methyl-17β-hydroxy-[5α]-androstan-3-one; 17β-hydroxy-1α-methyl-5α-androstan-3-one; 1alpha-methyl-17beta-hydroxy-5alphaandrostan-3-one; Testiwop; Androviron (+5) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| meta-fluorofentanyl | N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| meta-fluoroisobutyryl fentanyl | N-(3-fluorophenyl)-N-(1-phenylpiperidin-4-yl)isobutyramide; meta-fluoroisobutylryl fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| metazocine | 2,6-methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3,6,11-trimethyl-; methobenzmorphan | DEA Controlled Substance List: Schedule II | OPSS entry |
| methadone | Methadose; Amidone; Dolophine | DEA Controlled Substance List: Schedule II | OPSS entry |
| methadone-intermediate | 4-cyano-2-dimethylamino-4,4-diphenyl butane | DEA Controlled Substance List: Schedule II | OPSS entry |
| methamphetamine | metamfetamine(d-); ICE; Desoxyn; Speed; d-methamphetamine (+2) | DEA Controlled Substance List: Schedule II | OPSS entry |
| methandienone | metabolina; dianabol; methandrostenolone; 17α-methyl-17β-hydroxyandrost-1,4-dien-3-one; 17alpha-methyl-17beta-hydroxyandrost-1,4-dien-3-one (+7) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methandriol | androdiol; 17α-methyl-3β,17β-dihydroxyandrost-5-ene; Troformone; Stenediol; 17alpha-methyl-3beta,17beta-dihydroxyandrost-5-ene (+6) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methaqualone | Quaalude; Somnafac; Parest; Mandrax; Opitimil | DEA Controlled Substance List: Schedule I | OPSS entry |
| methasterone | 2alpha,17alpha-dimethyl-5alphaandrostan-17beta-ol-3-one; 17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one; superdrol; 2α,17α-dimethyl-5α-androstan-17β-ol-3-one; 17beta-hydroxy-2alpha,17alpha-dimethyl-5alpha-androstan-3-one (+4) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methcathinone | monomethylpropion; 2-(methylamino)-propiophenone; AL-463; AL-464; methylcathinone (+8) | DEA Controlled Substance List: Schedule I | OPSS entry |
| methenolone | 1-methyl-17β-hydroxy-5α-androst-1-en-3-one; Primobolan; Primobolan Depot; metenolone; (5α,17β)-17-hydroxy-1-methylandrost-1-en-3-one (+4) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methiopropamine | N-methyl-1-(thiophen-2-yl)propane-2-amine | DEA Controlled Substance List: Schedule I | OPSS entry |
| methohexital | Brevital; methohexitone; methohexitone sodium | DEA Controlled Substance List: Schedule IV | OPSS entry |
| methoxy polyethylene glycol-epoetin beta | MIRCERA® | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Methoxy polyethylene glycol-epoetin beta |
| methoxyacetyl fentanyl | 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| methoxydienone | 13-ethyl-3-methoxy-gona-2,5(10)-diene-17-one; methoxygonadiene; 13-beta-Ethyl-3-methoxy-gona-2,5(10)-dien-17-one; MAX-LMG; Max LMG | WADA S1: Anabolic Agents; FDA Warning Letter | FDA warning letter |
| methoxyphedrine | methedrone; 4-methoxymethcathinone | DEA Controlled Substance List: Schedule I | OPSS entry |
| methyl-1-testosterone | 17alpha-methyl-delta1-dihydrotestosterone; 17beta-hydroxy-17alpha-methyl-5alpha-androst-1-en-3-one; 17-alpha-methyl-1-testosterone; 17α-methyl-Δ1-dihydrotestosterone; 17-α-methyl-1-testosterone (+1) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methylclostebol | 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one; 4-Chloro-17β-hydroxy-17α-methylandrost-4-en-3-one; 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-en-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methyldesorphine | MK 57; 3-hydroxy-6,N-dimethyl-4,5-epoxymorphin-6-en | DEA Controlled Substance List: Schedule I | OPSS entry |
| methyldienolone | 17alpha-methyl-17beta-hydroxyestra4,9(10)-dien-3-one; 17beta-hydroxy-17alpha-methylestra-4,9-dien-3-one; 17β-hydroxy-17α-methylestra-4,9-dien-3-one; 17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methyldihydromorphine | methyl dihydromorphine; morphine, methyldihydro- | DEA Controlled Substance List: Schedule I | OPSS entry |
| methylephedrine | N-methylephedrine hydrochloride; methylpseudoephedrine; Tybraine; N-methylephedrine | Other reason | Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk |
| methylnaphthidate | 2-piperidineacetic acid, α-2-naphthalenyl-, methyl ester; HDMP-28; methyl 2-(naphthalen-2-yl)-2-(piperidin-2-yl)acetate; 2-piperidineacetic acid, alpha-2-naphthalenyl-, methyl ester; DL-threo-methylnaphthidate | Unapproved Drug | NIH NCATS Inxight Drugs entry: Methylnaphthidate |
| methylone | 2,3-methylenedioxymethcathinone; 1-(benzo[d][1,3]dioxol-4-yl)-2-(methylamino)propan-1-one); 2,3-MDMC; 3,4-methylenedioxy-N-methylcathinone | DEA Controlled Substance List: Schedule I | OPSS entry |
| methylphenidate | Tsentedrin; Concerta®; Ritalin®SR; Cotempla®XR-ODT; Aptensio XR® (+19) | DEA Controlled Substance List: Schedule II | OPSS entry |
| methylphenobarbital | mephobarbital; Mebaral | DEA Controlled Substance List: Schedule IV | OPSS entry |
| methylstenbolone | 2,17a-dimethyl-17b-hydroxy-5a-androst-1-en-3-one; M-Sten; Ultradrol | WADA S1: Anabolic Agents; FDA Warning Letter | FDA Warning Letter |
| methylsynephrine | 1-(4-hydroxyphenyl)-2-methylaminopropanol; Oxyephedrin; 4‐[1‐hydroxy‐2‐(methylamino)propyl]phenol; Suprifene; Supriphen (+16) | FDA Statement | FDA: Methylsynephrine in Dietary Supplements |
| methyltestosterone | Virilon; 17α-methyl-17β-hydroxyandrost-4-en-3-one; 17alpha-methyl-17beta-hydroxyandrost-4-en-3-one; 17β-hydroxy-17α-methylandrost-4-en-3-one; Android (+3) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methylthioninium chloride | methylene blue anhydrous; methylene blue; methylene blue | Prescription drug | NIH NCATS Inxight Drugs entry: Methylene blue |
| methyltrienolone | metribolone; 17beta-hydroxy-17alpha-methylestra-4,9,11-trien-3-one; 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one; 17α-methyl-17β-hydroxyestra-4,9-11-trien-3-one; 17alpha-methyltrienolone | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| methyprylon | Noludar | DEA Controlled Substance List: Schedule III | OPSS entry |
| metodesnitazene | N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine; 2-(2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N,N-diethylethanamine; N,N-diethyl-N-(2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethyl)amine; benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-methoxybenzyl)-; N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethanamine (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| metolazone | Zaroxolyn®; Mykrox® | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Metolazone |
| metonitazene | N,N-diethyl-2-[(4-methoxyphenyl)methyl]-5-nitro-1H-benzimidazole-1-ethanamine; benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-methoxybenzyl)-5-nitro-; N,N-diethyl-2-[2-[(4-methoxyphenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamine; 1H-benzimidazole-1-ethanamine, N,N-diethyl-2-((4-methoxyphenyl)methyl)-5-nitro-; N,N-diethyl-2-((4-methoxyphenyl)methyl)-5-nitro-1H-benzimidazole-1-ethanamine (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| metopon | dihydro-6-methylmorphinone; methyldihydromorphinone; 5-methyldihydromorphinone; 5-methylhydromorphone | DEA Controlled Substance List: Schedule II | OPSS entry |
| MGM-15 | dihydro-7-hydroxymitragynine | DEA Controlled Substance List: Schedule I | OPSS entry |
| MGM-16 | 9-fluoro-dihydro-7-hydroxymitragynine | DEA Controlled Substance List: Schedule I | OPSS entry |
| mibolerone | 7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one; Cheque; Cheque drops; Matenon; 7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one (+1) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| midazolam | Versed | DEA Controlled Substance List: Schedule IV | OPSS entry |
| mitochondrial open reading frame of the 12S rRNA-c | MOTS-c; mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| mitragynine pseudoindoxyl | pseudoindoxyl; MP; MGPI | DEA Controlled Substance List: Schedule I | OPSS entry |
| MK-677 | mk677; ibutamoren mesylate; MK 0677; Crescendo; 2-amino-N-((R)-2-(benzyloxy)-1-((1-(methylsulfonyl)spiro(indoline-3,4'-piperidin)-1'-yl)carbonyl)ethyl)-2-methyl-propionamide monomethanesulfonate (+5) | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| MMB-CHMICA | methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate; AMB-CHMICA | DEA Controlled Substance List: Schedule I | OPSS entry |
| MMB-FUBICA | methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate | DEA Controlled Substance List: Schedule I | OPSS entry |
| MMDA | 5-methoxy-3,4-methylenedioxy-amphetamine; 5-methoxy-3,4-methylenedioxyamphetamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| modafinil | benzhydrylsulfinylacetamide; Sparlon; modafinilum; Provigil; modafinilo (+3) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| molidustat | BAY 85-3934 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| moramide-intermediate | 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid | DEA Controlled Substance List: Schedule II | OPSS entry |
| morpheridine | TA 1; ethyl 1-(2-morpholin-4-ylethyl)-4-phenylpiperidine-4-carboxylate; morpholinoethyl-norpethidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| morphine | morphine methylsulfonate; morphine methylbromide; Roxanol; Oramorph; MSIR (+3) | DEA Controlled Substance List: Schedule II | OPSS entry |
| mozavaptan | WADA S5: Diuretics and Masking Agents | OPSS entry | |
| MPHP | 4'-methyl-alpha-pyrrolidinohexiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one; 4'-methyl-alpha-pyrrolidinohexanophenone | DEA Controlled Substance List: Schedule I | OPSS entry |
| MPPP | 1-methyl-4-phenyl-4-propionoxypiperidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| MT-45 | 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine | DEA Controlled Substance List: Schedule I | OPSS entry |
| myo-inositol trispyrophosphate | ITPP; ITPP cpd; OXY111A; inositol trispyrophosphate | Military policy | DoDI 6130.06 Use of Dietary Supplements in the DoD |
| myostatin propeptide | WADA S4: Hormone and Metabolic Modulators | OPSS entry | |
| myrophine | benzylmorphinyl myristate; myrophinium; myristylbenzylmorphine; 3-benzylmorphine 6-myristate; 3-benzyloxy-6-myristoyloxymorphine (+1) | DEA Controlled Substance List: Schedule I | OPSS entry |
| N,N-dimethylamphetamine | N,N-alpha-trimethylphenethylamine; dimethylamphetamine; dimetamfetamine; N,N-alpha-trimethyl-benzeneethanamine | DEA Controlled Substance List: Schedule I | OPSS entry |
| N,N-dimethylethylamine | 1,3-dimethylethylamine; dimethylethylamine; DMEA; ethanamine, N,N-dimethyl-; ethylamine, N,N-dimethyl- (+5) | Other reason | Toxic volatile industrial chemical |
| N-benzylpiperazine | 1-benzylpiperazine tartrate; 1-benzylpiperazine dihydrochloride; benzylpiperazine; BZP; 1-benzylpiperazine fumarate (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethyl-1-phenylcyclohexylamine | PCE; (1-phenylcyclohexyl)ethylamine; cyclohexamine; N-(1-phenylcyclohexyl)ethylamine; ethylamine analog of phencyclidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethyl-3-piperidyl benzilate | JB 323 | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethyl-N-methylcathinone | DEA Controlled Substance List: Schedule I | OPSS entry | |
| N-ethylamphetamine | ethylamphetamine; etilamfetamine; NEA; Adiparthrol; Apetinil | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethylbuphedrone | NEB | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethylhexedrone | 2-(ethylamino)-1-phenylhexan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-ethylpentylone | βk-ethyl-K; β-keto-ethylbenzodioxolylpentanamine; βk-EBDP; ephylone; 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-methyl-3-piperidyl benzilate | JB 336 | DEA Controlled Substance List: Schedule I | OPSS entry |
| N-methyltyramine | p-(2-(Methylamino)ethyl)phenol; methyl tyramine; NMT; p-(2-methylaminoethyl)phenol; 4-[2-(methylamino)ethyl]phenol (+10) | FDA Warning Letter | FDA Warning Letter |
| N-pyrrolidino etonitazene | (2-(4-ethoxybenzyl)-5-nitro-1-(2- (pyrrolidin-1-yl)ethyl)-1H-benzimidazole); 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)1Hbenzimidazone; 2-[(4-ethoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)benzimidazole; etonitazepyne ; 2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo(d)imidazole | DEA Controlled Substance List: Schedule I | OPSS entry |
| nabilone | Cesamet; (+)-trans-3-(1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one | DEA Controlled Substance List: Schedule II | OPSS entry |
| nafarelin | LHRH, 6(D-NAL(2)) | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Nafarelin |
| nalorphine | Nalline | DEA Controlled Substance List: Schedule III | OPSS entry |
| nandrolone | nandrolone enanthate; duraboin; 19-nortestosterone; 17β-hydroxyestr-4-en-3-one; deca-durabolin (+5) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| naphthalene | albocarbon; dezodorator; tar camphor; white tar | DoDI 1010.16 | OPSS entry |
| naphyrone | α-naphyrone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one; naphthylpyrovalerone | DEA Controlled Substance List: Schedule I | OPSS entry |
| nefiracetam | N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide; N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl) acetamide; 2-oxo-1-pyrrolidineaceto-2',6'-xylidide | Unapproved Drug | NIH NCATS Inxight Drugs entry: Nefiracetam |
| nicocodeine | nicocodine; 6-nicotinoylcodeine; lyopect; nicotinic acid, ester with codeine | DEA Controlled Substance List: Schedule I | OPSS entry |
| nicomorphine | Vilan | DEA Controlled Substance List: Schedule I | OPSS entry |
| nimetazepam | methylnitrazepam; 1,3-dihydro-1-methyl-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one; Elimin; Erimin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| nitrazepam | Mogadon | DEA Controlled Substance List: Schedule IV | OPSS entry |
| NM2201 | naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; CBL2201 | DEA Controlled Substance List: Schedule I | OPSS entry |
| nor-NOHA | butanoic acid, 2-amino-4-(((hydroxyamino)iminomethyl)amino)-, (S)-; N-omega-hydroxy-L-norarginine; (2S)-4-[[amino-(hydroxyamino)methylidene]amino]-2-azaniumylbutanoate; Nomega-hydroxy-nor-L-arginine; N-omega-hydroxynor-L-arginine (+5) | Unapproved Drug | NIH NCATS Inxight Drugs entry: nor-NOHA |
| noracymethadol | [6-(methylamino)-4,4-diphenylheptan-3-yl] acetate; paracymethadol | DEA Controlled Substance List: Schedule I | OPSS entry |
| norandrostenediol | 19-nor-4-androstenediol; 19-nor-androstenediol; bolandiol; 3β-dihydronandrolone; 3beta-dihydronandrolone (+8) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| norandrostenedione | bolandione; 19-nor-4-androstenedione; 19-norandrost-4-ene-3,17-dione; 19-norandrost-4-en-3,17-dione; estr-4-ene-3β,17-dione (+5) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| norbenzoylecgonine | NBE; benzoylnorecgonine | DoDI 1010.16 | OPSS entry |
| norbolethone | norboletone; 13β,17α-diethyl-17β-hydroxygon-4-en-3-one; 17α-Ethyl-17β-hydroxy-18-methylestr-4-en-3-one; 13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one; Genabol | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| norclostebol | 4-chloro-17β-hydroxyestr-4-en-3-one; 4-chloro-17β-ol-estr-4-en-3-one; 4-chloro-17beta-hydroxyestr-4-en-3-one; Lentabol; Anabol-4-19 (+1) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| norcocaine | n-demethylcocaine | DoDI 1010.16 | OPSS entry |
| nordiazepam | nordazepam; dealkylprazepam; Madar; desmethyldiazepam; norprazepam (+1) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| norethandrolone | 17alpha-ethyl-17beta-hydroxyestr-4en-3-one; Pronabol; Solevar; Nilevar; 17α-ethyl-17β-hydroxyestr-4-en-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| norfenfluramine | DoDI 1010.16 | OPSS entry | |
| norfentanyl | N-phenyl-N-(piperidin-4-yl)propionamide | DEA Controlled Substance List: Schedule II | OPSS entry |
| norlevorphanol | 3-hydroxymorphinan; morphinan-3-ol | DEA Controlled Substance List: Schedule I | OPSS entry |
| normethadone | phenyldimazone | DEA Controlled Substance List: Schedule I | OPSS entry |
| normethandrolone | methylestrenolone; 17β-hydroxy-17α-methylestr-4-en-3-one; methylnortestosterone; Matronal; 17α-methyl-19-nortestosterone (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| normorphine | DEA Controlled Substance List: Schedule I | OPSS entry | |
| noroxymorphone | 7,8-dihydro-14-hydroxynormorphinone; (5alpha)-4,5-Epoxy-3,14-dihydroxymorphinan-6-one | DEA Controlled Substance List: Schedule II | OPSS entry |
| norpipanone | Hoechst 10495; Orfenso; 3-hexanone, 4,4-diphenyl-6-(1-piperidinyl)- | DEA Controlled Substance List: Schedule I | OPSS entry |
| nortadalafil | Unapproved Drug; FDA Warning Letter | FDA Warning Letter | |
| Nymphaea caerulea | blue lotus; blue lotus (Nymphaea caerulea); Egyptian water lily; nuciferine; apomorphine | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| octopamine | 4-(2-amino-1-hydroxyethyl)phenol; Norden; 1-(p-hydroxyphenyl)-2-aminoethanol; alpha-aminoethyl-4-hydroxybenzylalkohol; Norphen (+14) | FDA Warning Letter | FDA Warning Letter |
| oliceridine | N-[(3-methoxythiophen-2-yl)methyl] ({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro [4.5]decan-9-yl]ethyl})amine fumarate; N-[(3-methoxythiophen-2-yl)methyl] ({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro [4.5]decan-9-yl]ethyl{time} )amine fumarate; N-[(3-Methoxythiophen-2-yl)methyl]-2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethanamine | DEA Controlled Substance List: Schedule II | OPSS entry |
| olodaterol | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Olodaterol | |
| omberacetam | GVS 111; Noopept; ethyl phenylacetyl-pro-gly; GVS-111; noopept (N-phenylacetyl-L-prolyglycine ethyl ester) (+1) | Unapproved Drug | DoJ Press Release |
| opium | paregoric; opium, raw; opium fluid extract; powdered opium; gum opium (+10) | DEA Controlled Substance List: Schedule II | OPSS entry |
| oripavine | DEA Controlled Substance List: Schedule II | OPSS entry | |
| ortho-fluoroacryl fentanyl | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-fluorobutyryl fentanyl | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide; 2-fluorobutyryl fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-fluorofentanyl | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide; 2-fluorofentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-fluorofuranyl fentanyl | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-fluoroisobutyryl fentanyl | N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-methyl acetylfentanyl | 2-methylacetylfentanyl; N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| ortho-methyl methoxyacetylfentanyl | 2-methyl methoxyacetyl fentanyl; 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| osilodrostat | Isturisa | WADA S1: Anabolic Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Osilodrostat |
| ospemifene | 2-(4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy)ethanol; 2-(p-((Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol; Osphena; CCRIS 9205; Fc-1271 (+5) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Ospemifene |
| oxabolone | 4,17beta-dihydroxyestr-4-en-3-one; 4,17β-dihydroxy-estr-4-en-3-one; 4,17β-dihydroxyestr-4-en-3-one; 19-norandrost-4-ene-4,17β-diol-3-one; 4-hydroxy-19-nortestosterone | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| oxandrolone | Protivar; SC 11585; SC11585; 2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-; Oxandrin (+14) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| oxazepam | Serenid-D; Serax | DEA Controlled Substance List: Schedule IV | OPSS entry |
| oxazolam | Convertal; Serenal | DEA Controlled Substance List: Schedule IV | OPSS entry |
| oxiracetam | 4-hydroxy-2-oxo-pyrrolidinacetamide | Unapproved Drug | FDA Designated Orphan Drug |
| oxycodone | OxyContin; Roxicodone; Endocet; Percocet; Roxicet | DEA Controlled Substance List: Schedule II | OPSS entry |
| oxyguno | 4-chloro-17alpha-methyl-17beta-hydroxy-androst-4-ene-3,11-dione; 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione | DEA Controlled Substance List: Schedule III | OPSS entry |
| oxymesterone | Oranabol 10; Balnimax; 17alpha-methyl-4,17beta-dihydroxyandrost-4-en-3-one; 4,17β-dihydroxy-17α-methylandrost-4-en-3-one; Anamidol (+3) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| oxymetholone | 17β-hydroxy-2-hydroxymethylene-17α-methyl-5α-androstan- 3-one; anasterone; Anadrol; 17β-Hydroxy-2-hydroxymethylidene-17α-methyl-3-androstanone; Pardroyd (+7) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| oxymorphone | Numorphan | DEA Controlled Substance List: Schedule II | OPSS entry |
| p-hydroxybenzoylecgonine | pOHBE; 4-hydroxybenzoylecgonine | DoDI 1010.16 | OPSS entry |
| p-hydroxycocaine | 4'-hydroxybenzoylecgonine methyl ester; 4'-hydroxycocaine | DoDI 1010.16 | OPSS entry |
| para-chloroisobutyryl fentanyl | N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-fluoro furanyl fentanyl | N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-fluorobutyryl fentanyl | N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-fluorofentanyl | N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-methoxybutyryl fentanyl | N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-methoxyfuranyl fentanyl | N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-methoxymethamphetamine | PMMA; 1-(4-methoxyphenyl)-N-methylpropan-2-amine | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-methylcyclopropyl fentanyl | N-(4-methylphenyl)-N-(1-phenylpiperidin-4-yl)cyclopropanecarboxamide; para-methylcyclopropylfentanyl; N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| para-methylfentanyl | 4-methylfentanyl; N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| parahexyl | Synhexyl; 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran | DEA Controlled Substance List: Schedule I | OPSS entry |
| paraldehyde | Paral | DEA Controlled Substance List: Schedule IV | OPSS entry |
| PCC | 1-piperidinocyclohexanecarbonitrile | DEA Controlled Substance List: Schedule II | OPSS entry |
| peginesatide | hematide | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| pegmolesatide | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| pemoline | Cylert | DEA Controlled Substance List: Schedule IV | OPSS entry |
| pentazocine | Talacen; Talwin NX; Talwin Compound; Talwin | DEA Controlled Substance List: Schedule IV | OPSS entry |
| pentedrone | 4-methylbuphedrone; 2-(methylamino)-1-phenylpentan-1-one; α-methylaminovalerophenone | DEA Controlled Substance List: Schedule I | OPSS entry |
| pentobarbital | Nembutal | DEA Controlled Substance List: Schedule II | OPSS entry |
| pentylone | propylone; bk-DMBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1- one; bk-MBDP; 3',4'-methylenedioxy-N-propylaminocathinone (+3) | DEA Controlled Substance List: Schedule I | OPSS entry |
| PEPAP | 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine | DEA Controlled Substance List: Schedule I | OPSS entry |
| perampanel | Fycompa; 2-(2-oxo-l-phenyl-5-pyridin-2-yl-l,2-dihydropyridin-3-yl) benzonitrile | DEA Controlled Substance List: Schedule III | OPSS entry |
| pethidine | meperidine; Demerol; Mepergan | DEA Controlled Substance List: Schedule II | OPSS entry |
| pethidine-intermediate-A | 4-cyano-1-methyl-4-phenylpiperidine; meperedine intermediate-A | DEA Controlled Substance List: Schedule II | OPSS entry |
| pethidine-intermediate-B | ethyl-4-phenylpiperidine-4-carboxylate; normeperidine; meperedine intermediate-B | DEA Controlled Substance List: Schedule II | OPSS entry |
| pethidine-intermediate-C | 1-methyl-4-phenylpiperidine-4-carboxylic acid; meperedine intermediate-C | DEA Controlled Substance List: Schedule II | OPSS entry |
| petrichloral | Pentaerythritol chloral; Periclor | DEA Controlled Substance List: Schedule IV | OPSS entry |
| peyote | Lophophora williamsii Lemaire | DEA Controlled Substance List: Schedule I | OPSS entry |
| phenadoxone | 6-morpholino-4,4-diphenyl-3-heptanone; 4,4-diphenyl-6-morpholino-3-heptanone; phenodoxone | DEA Controlled Substance List: Schedule I | OPSS entry |
| phenampromide | N-(1-methyl-2-piperidinoethyl)propionanilide; fenampromide; phenampromid | DEA Controlled Substance List: Schedule I | OPSS entry |
| phenazocine | Prinadol; Narphen | DEA Controlled Substance List: Schedule II | OPSS entry |
| phencyclidine | Semylan; 1-(1-phenylcyclohexyl)piperidine; PCP | DEA Controlled Substance List: Schedule II | OPSS entry |
| phendimetrazine | Prelu-2; Statobex; Melfiat; Bontril; Plegine | DEA Controlled Substance List: Schedule III | OPSS entry |
| phenibut | β-phenyl-GABA; aminophenylbutyric acid; phenygam; phenigam; phenylgamma (+19) | FDA Statement | FDA: Phenibut in Dietary Supplements |
| phenmetrazine | Preludin | DEA Controlled Substance List: Schedule II | OPSS entry |
| phenobarbital | Bellergal-S; Luminal | DEA Controlled Substance List: Schedule IV | OPSS entry |
| phenomorphan | DEA Controlled Substance List: Schedule I | OPSS entry | |
| phenoperidine | Operidine; Lealgin | DEA Controlled Substance List: Schedule I | OPSS entry |
| phentermine | Phentrol; Lonamin; Fastin; normephentermine; phentermine hydrochloride (+14) | DEA Controlled Substance List: Schedule IV | OPSS entry |
| phenyl fentanyl | benzoyl fentanyl; N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| phenylacetone | P2P; benzyl methyl ketone; methyl benzyl ketone; phenyl-2-propanone | DEA Controlled Substance List: Schedule II | OPSS entry |
| pholcodine | Lantuss; Pholcolin; Adaphol; Codisol; Copholco | DEA Controlled Substance List: Schedule I | OPSS entry |
| picamilon | 4-(pyridine-3-carbonylamino) butanoic acid; pikamilon; monosodium 4-((3-pyridinylcarbonyl)amino)butanoate; pikatropin; N-nicotinoyl-gamma-aminobutyric acid sodium salt (+7) | Unapproved Drug; FDA Statement | FDA: Picamilon in Dietary Supplements |
| piminodine | DEA Controlled Substance List: Schedule II | OPSS entry | |
| pinazepam | Domar | DEA Controlled Substance List: Schedule IV | OPSS entry |
| Piper methysticum | kava kava; noble kava; kawain; kava; kava root (+4) | Military policy | DoDI 1010.04 Problematic Substance Use by DoD Personnel and DoDI 6130.06 Use of Dietary Supplements in the DoD |
| pipradrol | Stimolag Fortis; Detaril | DEA Controlled Substance List: Schedule IV | OPSS entry |
| piracetam | 2-oxo-1-pyrrolidineacetamide; Ciclofalina; Nootropil; 2-pyrrolidinoneacetamide; Pirazetam (+32) | FDA Statement | FDA Statement |
| piritramide | Piridolan | DEA Controlled Substance List: Schedule I | OPSS entry |
| poppy straw | concentrate of poppy straw; CPS; poppy heads; opium poppy capsules | DEA Controlled Substance List: Schedule II | OPSS entry |
| pralmorelin | growth hormone-releasing peptide-2; GHRP-2 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| pramiracetam | 1-pyrrolidineacetamide, N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-; CI-879 free base; N-(2-(diisopropylamino)ethyl)-2-oxo-1-pyrrolidineacetamide | Unapproved Drug | FDA Orphan Drug Designation Withdrawn |
| prazepam | Centrax | DEA Controlled Substance List: Schedule IV | OPSS entry |
| pregabalin | (S)-3-(aminomethyl)-5-methylhexanoic acid; Lyrica | DEA Controlled Substance List: Schedule V | OPSS entry |
| pregnenolone | 5-pregnen-3-β-ol-20-one; pregnenolona; delta5-pregnenolone; Skinostelon; Pregnetan (+22) | Unapproved Drug | Unfinished Drug Product |
| probenecid | Probalan | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Probenecid |
| procaterol | procaterol hydrochloride hydrate; procaterol hydrochloride | WADA S3: Beta-2 Agonists | OPSS entry |
| proheptazine | dimepheprimine; 1,3-dimethyl-4-phenyl-4-propionyloxyazacycloheptane | DEA Controlled Substance List: Schedule I | OPSS entry |
| properidine | isopropyl 1-methyl-4-phenylisonipecotate; gevelina; ipropethidine; isopedine | DEA Controlled Substance List: Schedule I | OPSS entry |
| propiram | Algeril | DEA Controlled Substance List: Schedule I | OPSS entry |
| prostanozol | 17β-[(Tetrahydro-2H-pyran-2-yl)oxy]-5α-androst-2-eno[3,2- c]pyrazole; 17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α-androstane; [3,2-c]pyrazole-5alpha-androstan-17beta-ol; 17β-hydroxy-5α-androstano[3,2-c]pyrazole; 17beta-hydroxy-5alpha-androstano[3,2c]pyrazole (+2) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| protonitazene | N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1- yl)ethan-1-amine; N,N-diethyl-2-[5-nitro-2-[(4-propoxyphenyl)methyl]benzimidazol-1-yl]ethanamine; propoxynitazene | DEA Controlled Substance List: Schedule I | OPSS entry |
| pseudoephedrine | pseudoephedrine HCl; (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol; pseudoephedrine hydrochloride; Isoephedrine; d-Isoephedrine (+1) | OTC drug | FDA: Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine… |
| psilocybin | DEA Controlled Substance List: Schedule I | OPSS entry | |
| psilocyn | psilocin | DEA Controlled Substance List: Schedule I | OPSS entry |
| PV8 | alpha-pyrrolidinoheptaphenone; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one | DEA Controlled Substance List: Schedule I | OPSS entry |
| pyrovalerone | Centroton; Thymergix | DEA Controlled Substance List: Schedule V | OPSS entry |
| pyrrole | 1h-pyrrole; imidole; azole; 1-aza-2,4-cyclopentadiene; divinylenimine | DoDI 1010.16 | OPSS entry |
| quazepam | Doral | DEA Controlled Substance List: Schedule IV | OPSS entry |
| quinbolone | 17beta-(1-cyclopenten-1-yloxy)androsta-1,4-dien-3-one; quinbolona; androsta-1,4-dien-3-one, 17-(1-cyclopenten-1-yloxy)-, (17beta); 17beta-(1-cyclopentenyloxy)-1,4-androstadien-3-one; 17β-(1-cyclopentenyloxy)-1,4-androstadien-3-on (+6) | WADA S1: Anabolic Agents | OPSS entry |
| quinethazone | Hydromox | WADA S5: Diuretics and Masking Agents | OPSS entry |
| QUPIC | PB-22; quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate | DEA Controlled Substance List: Schedule I | OPSS entry |
| R3-IGF-1 | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| racemethorphan | DL-methorphan; 3-methoxy-17-methylmorphinan; racemethorphan hydrobromide | DEA Controlled Substance List: Schedule II | OPSS entry |
| racemoramide | dimorlin; DL-moramide | DEA Controlled Substance List: Schedule I | OPSS entry |
| racemorphan | Dromoran | DEA Controlled Substance List: Schedule II | OPSS entry |
| ractopamine | WADA S1: Anabolic Agents | OPSS entry | |
| RAD-150 | 2-[5-chloropentyl(methyl)amino]-N-(2,6-dimethylphenyl)acetamide; sustalone; TLB-150 benzoate; (2S,3R)-3-[(cyanophenyl)-1,3,4-oxadiazoll-2-yl]-3-[(2-methyl-3-chloro-4-cyanphenyl)amino]-2-propyl alcohol benzoate; (2S,3R)-3-[(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-3-[(2- methyl-3-chloro-4-cyanphenyl)amino]-2-propyl alcohol benzoate (+15) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| raloxifene | Evista; raloxifene hydrochloride; CCRIS 7129; raloxifeno; LY139481 (+8) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Raloxifene |
| reldesemtiv | CK-2127107 | WADA S0: Non-approved Substances | OPSS entry |
| remifentanil | Ultiva | DEA Controlled Substance List: Schedule II | OPSS entry |
| remimazolam | methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4yl]propanoate benzenesulfonic acid; 4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid; 8-bromo-1-methyl-6-(2-pyridinyl)-(4S)-methyl ester; benzenesulfonate (1:1); byfavo | DEA Controlled Substance List: Schedule IV; Prescription drug | NIH NCATS Inxight Drugs entry: remimazolam |
| reproterol | 1H-purine-2,6-dione, 7-(3-((2-(3,5-dihydroxyphenyl)-2-hydroxyethyl)amino)propyl)-3,7-dihydro-1,3-dimethyl-; 7-(3-((beta,3,5-trihydroxyphenethyl)amino)propyl)theophylline; 7-(3-((β,3,5-trihydroxyphenethyl)amino)propyl)theophylline | WADA S3: Beta-2 Agonists | OPSS entry |
| rismorelin | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| roxadustat | FG-4592 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| S-23 | 3-(4-cyanophenoxy)-N-(4-cyano-3-trifluoromethylphenyl)-2-hydroxy-2-methylpropionamide; 1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride; CCTH-methylpropionamide; (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide; 1-phenyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (+8) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| S-40503 | S 40503; s 40503; s40503; 2-quinolineethanol, 4-(dimethylamino)-1,2,3,4-tetrahydro-β,β-dimethyl-6-nitro-; 2-(4-(dimethylamino)-6-nitro-1,2,3,4-tetrahydroquinolin-2-YL)-2-methylpropan-1-ol (+2) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| S48168 (ARM210) | WADA S0: Non-approved Substances | OPSS entry | |
| salbutamol | albuterol | WADA S3: Beta-2 Agonists | OPSS entry |
| salmeterol | Serevent | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Salmeterol |
| Salvia divinorum | Divine Mexican Mint; Pipiltzintzintli; divinorin A; salvinorin A; Leaves of the Virgin Shepherdess (+15) | Military policy | Salvia and drug testing |
| SARM | selective androgen receptor modulator; SARMs | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| SARM S1 | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry | |
| SARM S9 | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry | |
| secobarbital | Quinalbarbitone; Tuinal; Seconal | DEA Controlled Substance List: Schedule II | OPSS entry |
| semax | Unapproved Drug | Unfinished Drug Product | |
| serdexmethylphenidate | 3-[[[(1S)-1-carboxy-2-hydroxyethyl]-amino]carbonyl]-1-[[[[(2R)-2-[(1R)-2-methoxy-2-oxo-1-phenylethyl]-1-piperidinyl]carbonyl]oxy]methyl]pyridinium chloride | DEA Controlled Substance List: Schedule IV; Prescription drug | NIH NCATS Inxight Drugs entry: serdexmethylphenidate |
| sermorelin | Geref | WADA S2: Peptide Hormones, Growth Factors, etc.; Discontinued drug | NIH NCATS Inxight Drugs entry: Sermorelin |
| sibutramine | sibutraminum; mono-desmethylsibutramine; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; sibutramine hydrochloride monohydrate; BTS-54524 (+8) | DEA Controlled Substance List: Schedule IV | FDA Drug Safety Communication Recommends Against Use |
| sildenafil | Viagra | Prescription drug | NIH NCATS Inxight Drugs entry: Sildenafil |
| sodium tetrachloroaurate | tetrachloroaurate (1-) sodium; gold chloride sodium; sodium tetrachloroaurate (1-); tetrachloroauric (3+) acid, sodium salt; sodium tetrachloroaurate (III) (+7) | Unapproved Drug | Finished Drug Product |
| solriamfetol | benzenepropanol, beta-amino-, carbamate (ester); 2-amino-3-phenylpropyl carbamate; (2R)-2-amino-3-phenylpropyl carbamate; Sunosi | DEA Controlled Substance List: Schedule IV; Prescription drug | NIH NCATS Inxight Drugs entry: solriamfetol |
| somapacitan | somapacitan-geco | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Somapacitan |
| somatorelin | WADA S2: Peptide Hormones, Growth Factors, etc.; DoDI 1010.16 | OPSS entry | |
| somatrogon | Ngenla; NGENLA | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| sotatercept | ACE-011 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| spironolactone | CaroSpir; Aldactone; spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); Verospiron | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Spironolactone |
| SR-18 | 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole; RCS-8 | DEA Controlled Substance List: Schedule I | OPSS entry |
| SR-19 | RCS-4; 1-pentyl-3-[(4-methoxy)-benzoyl]indole; 1-pentyl-3-(4-methoxybenzoyl)indole | DEA Controlled Substance List: Schedule I | OPSS entry |
| SR-9009 | ethyl 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]pyrrolidine-1-carboxylate; SR 9009; 1-pyrrolidinecarboxylic acid, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-, ethyl ester; Stenabolic; SR9009 | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| SR-9011 | 3-[[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]methyl]-N-pentylpyrrolidine-1-carboxamide; SR9011; 1-pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl- | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| stanozolol | 17β-hydroxy-17α-methylandrostano(3,2-c)pyrazole; 17alpha-methyl-17beta-hydroxy-5alphaandrost-2-eno[3,2-c]-pyrazole; 17α-methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole; androstanazol; Winstrol (+4) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| stenbolone | 17beta-hydroxy-2-methyl-5alpha-androst-1-en-3-one; 17β-hydroxy-2-methyl-[5α]-androst-1-en-3-one | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| sulbutiamine | BRN 0741531; N,N'-(dithiobis(2-(2-hydroxyethyl)-1-methylvinylene))bis(N-((4-amino-2-methyl-5-pyrimidinyl)methyl)formamide) diisobutyrate (ester); Bisibutiamin; UNII-42NCM1BW43; O,O'-diisobutyrylthiamine disulfide (+8) | FDA Warning Letter | FDA Warning Letter |
| sulfondiethylmethane | tetronal; 3,3-bis(ethylsulfonyl)pentane | DEA Controlled Substance List: Schedule III | OPSS entry |
| sulfonethylmethane | DEA Controlled Substance List: Schedule III | OPSS entry | |
| sulfonmethane | trional; methylsulfonal; 2,2-bis(ethylsulfonyl)butane | DEA Controlled Substance List: Schedule III | OPSS entry |
| sunifiram | 1-benzoyl-4-propanoylpiperazine; piperazine, 1-benzoyl-4-(1-oxopropyl)-; DM-235; 1-benzyl-4-propanoylpiperazine; 1-propanone, 1-(4-benzoyl-1-piperazinyl)- | Unapproved Drug | NIH NCATS Inxight Drugs entry: Sunifiram |
| suvorexant | [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; MK-4305; Belsomra | DEA Controlled Substance List: Schedule IV | OPSS entry |
| synthetic cannabinoids | pyrrolo-benzoxazine; cannabinoid derivative; indazole carboxamide cannabinoid; naphthoylindole cannabinoids; indole carboxylate cannabinoid (+3) | DoDI 1010.16 | OPSS entry |
| tabimorelin | D-phenylalaninamide, N-((2E)-5-amino-5-methyl-1-oxo-2-hexen-1-YL)-N-methyl-3-(2-naphthalenyl)-D-alanyl-N,Nα-dimethyl-; D-phenylalaninamide, N-((2E)-5-amino-5-methyl-1-oxo-2-hexen-1-YL)-N-methyl-3-(2-naphthalenyl)-D-alanyl-N,Nalpha-dimethyl- | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| tadalafil | Cialis | Prescription drug | NIH NCATS Inxight Drugs entry: Tadalafil |
| talbutal | Lotusate | DEA Controlled Substance List: Schedule III | OPSS entry |
| tamoxifen | Soltamox; ICI-47699; ICI46474; Novaldex; ICI47699 (+28) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Tamoxifen |
| tapentadol | DEA Controlled Substance List: Schedule II | OPSS entry | |
| tauroursodeoxycholic acid | TUDCA; ursodoxicoltaurine; tuaroursodeoxycholic acid; tauroursodeoxycholic acid (TUDCA) | Discontinued drug | NIH NCATS Inxight Drugs entry: ursodoxicoltaurine |
| TB-500 | Ac-LKKTETQ | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| temazepam | Restoril | DEA Controlled Substance List: Schedule IV | OPSS entry |
| terbutaline | terbutaline sulfate | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Terbutaline |
| tesamorelin | egrifta | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Tesamorelin |
| tesofensine | NS-2330 | Unapproved Drug | FDA Designated Orphan Drug |
| testolactone | 1 dehydrotestolactone; 1-dehydrotestololactone; testolattone; EINECS 213-534-6; testolacton (+20) | DEA Controlled Substance List: Schedule III; WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| testosterone | testosterone undecanoate; testosterone propionate; Androlan; 17beta-hydroxyandrost-4-en-3-one; Andriol (+12) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| tetracosactide | cosyntropin | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Cosyntropin |
| tetrahydrocannabinols | delta-9-THC; 6 trans tetrahydrocannabinol; delta 8; HHC; 3, 4 trans tetrahydrocannabinol (+16) | DEA Controlled Substance List: Schedule I | OPSS entry |
| tetrahydrofuranyl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| tetrahydrogestrinone | 13β,17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one; 13beta,17alpha-diethyl-17betahydroxygon-4,9,11-trien-3-one; 17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien-3-one; 17β-Hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3- one; THG | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| tetrazepam | Myolastan; Musaril | DEA Controlled Substance List: Schedule IV | OPSS entry |
| thebacon | acetylhydrocodone; Acedicon; Thebacetyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| thebaine | paramorphine; codeine methyl enol ether; 3-O-methyl-oripavin | DEA Controlled Substance List: Schedule II | OPSS entry |
| thiafentanil | Thianil | DEA Controlled Substance List: Schedule II | OPSS entry |
| thiamylal | Surital | DEA Controlled Substance List: Schedule III | OPSS entry |
| thiazolidene | tetrahydrothiazole; 1,3-thiazolidine; 1-thia-3-azacyclopentane | DoDI 1010.16 | OPSS entry |
| thiofentanyl | N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]propanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| thiofuranyl fentanyl | N-(1-phenethylpiperidin-4-yl)-Nphenylthiophene-2-carboxamide; 2-thiofuranyl fentanyl; thiophene fentanyl | DEA Controlled Substance List: Schedule I | OPSS entry |
| thiomesterone | Emdabol; 1,7-bis(acetylthio)-17β-hydroxy-17α-methyl-androst-4-en-3- one | WADA S1: Anabolic Agents; DoDI 1010.16 | OPSS entry |
| thiopental | Pentothal | DEA Controlled Substance List: Schedule III | OPSS entry |
| THJ-2201 | [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone | DEA Controlled Substance List: Schedule I | OPSS entry |
| thymosin beta 4 | thymosin-β4; Timbetasin; Tβ4 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| tianeptine | Coaxil; tianeptine acid; 7-[(3-chloro-6-methyl-5,5-dioxo-11H-benzo[c][2,1]benzothiazepin-11-yl)amino] heptanoic acid; tianeptine sulfate; Tianaa (+6) | FDA Statement | FDA: Tianeptine |
| tibolone | 17-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one; 17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one | WADA S1: Anabolic Agents | OPSS entry |
| tiletamine | Telazol; 2-(ethylamino)-2-(2-thienyl)-cyclohexanone | DEA Controlled Substance List: Schedule III | OPSS entry |
| tilidine | Lak; Kitadol; Tilsa; Tilidate; Valoron | DEA Controlled Substance List: Schedule I | OPSS entry |
| tirasemtiv | CK-2017357 | WADA S0: Non-approved Substances | OPSS entry |
| TMA | 3,4,5-trimethoxyamphetamine; 3,4,5-trimethoxy amphetamine; 2,4,5-trimethoxyamphetamine; TMA-6; escaline (+2) | DEA Controlled Substance List: Schedule I | OPSS entry |
| tolvaptan | Jynarque | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Tolvaptan |
| torasemide | torsemide; Demadex | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Torsemide |
| toremifene | Fareston; GTx 006; toremifeno; NK 622; toremifene citrate (+9) | WADA S4: Hormone and Metabolic Modulators; Prescription drug | NIH NCATS Inxight Drugs entry: Toremifene |
| tramadol | 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol; tramadol hydrochloride | DEA Controlled Substance List: Schedule IV | OPSS entry |
| trenbolone | trenbolone enanthate; 17beta-trenbolone; Finaplix-S; Parabolan; 17 beta-acetoxyestr-4,9,11-trien-3-one (+8) | DEA Controlled Substance List: Schedule III; WADA S1: Anabolic Agents | OPSS entry |
| trestolone | MENT; trestolone phenylpropionate; 19-nor-methyltestosterone; 7α-methyl-19-nortestosterone; trestolone acetate [7a-methyl-17ß-hydroxyestr-4-en-3-one acetate] (+5) | WADA S1: Anabolic Agents | OPSS entry |
| tretoquinol | tretoquinol, (+)-; trimethoquinol; trimetoquinol | WADA S3: Beta-2 Agonists | OPSS entry |
| triacetyluridine | uridine triacetate; TAU; Xuriden | Prescription drug | NIH NCATS Inxight Drugs entry: Uridine triacetate |
| triamterene | 6-phenylpteridine-2,4,7-triamine; 2,4,7-triamino-6-phenylpteridine; Dyrenium | WADA S5: Diuretics and Masking Agents; Prescription drug | NIH NCATS Inxight Drugs entry: Triamterene |
| triazolam | Halcion | DEA Controlled Substance List: Schedule IV | OPSS entry |
| trimeperidine | Promedolum | DEA Controlled Substance List: Schedule I | OPSS entry |
| trimetazidine | Centrophène; 1-(2,3,4-trimethoxybenzyl)piperazine; dihydrochloride, trimetazidine; Idaptan; trimetazidinum (+10) | WADA S4: Hormone and Metabolic Modulators | OPSS entry |
| triptorelin | Triptodur; Arvekap | WADA S2: Peptide Hormones, Growth Factors, etc.; Prescription drug | NIH NCATS Inxight Drugs entry: Triptorelin |
| tulobuterol | alpha-((tert-butylamino)methyl)-O-chlorobenzyl alcohol; α-((tert-butylamino)methyl)-O-chlorobenzyl alcohol | WADA S3: Beta-2 Agonists | OPSS entry |
| U-47700 | 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| unifiram | DM-232; pyrrolo(1,2-A)pyrazin-6(2H)-one, 2-((4-fluorophenyl)sulfonyl)hexahydro-; 2-((4-fluorophenyl)sulfonyl)hexahydropyrrolo(1,2-A)pyrazin-6(2H)-one | Unapproved Drug | NIH NCATS Inxight Drugs entry: Unifiram |
| UR-144 | (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone | DEA Controlled Substance List: Schedule I | OPSS entry |
| vadadustat | AKB-6548 | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry |
| valeryl fentanyl | N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide | DEA Controlled Substance List: Schedule I | OPSS entry |
| vilanterol | GW-642444X; GW-642444; GW642444 | WADA S3: Beta-2 Agonists; Prescription drug | NIH NCATS Inxight Drugs entry: Vilanterol |
| vinbarbital | Delvinal; vinbarbitone | DEA Controlled Substance List: Schedule III | OPSS entry |
| vinpocetine | 3-α,16-α-apovincaminic acid ethyl ester; ethyl apovincamin-22-oate; Cavinton; Ceractin; ethyl (3α,16α)-eburnamenine-14-carboxylate (+6) | FDA Statement | FDA: Vinpocetine in Dietary Supplements |
| vosilasarm | RAD-140 testolone; Testolone; 2-chloro-4-[[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino]-3-methylbenzonitrile; RAD140; 2-chloro-4-((1R,2S)-1-(5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl)-2-hydroxypropylamino)-3-methylbenzonitrile (+3) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| xanthinol | 7-[2-hydroxy-3-[2-hydroxyethyl-methyl-amino)propyl]-1,3dimethylpurine-2,6-dione; xanthinol nicotinate; xantinol; Jupal | Unapproved Drug | NIH NCATS Inxight Drugs entry: xanthinol |
| xenon | WADA S2: Peptide Hormones, Growth Factors, etc. | OPSS entry | |
| xipamide | WADA S5: Diuretics and Masking Agents | OPSS entry | |
| YK-11 | YK-500; 19-norpregna-4,20-diene-21-carboxylic acid, 17,20-((1-methoxyethylidene)bis(oxy))-3-oxo-, methyl ester, (17alpha,20E)-; methyl(2E)-2-[(8R,9S,10R,13S,14S,17R)-2’-methoxy-2’,13-dimethyl-3-0x0spiro[1,2,6.7,8,9,10,11,12,14,15,16-dodecahydroyclopenta[; (17-α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3- oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester); YK 11 (+6) | WADA S1: Anabolic Agents; FDA Statement | Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more |
| zaleplon | Sonata | DEA Controlled Substance List: Schedule IV | OPSS entry |
| zeranol | (3S,7R)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10,11,12-decahydro-1H-2-benzoxacyclotetradecin-1-one | WADA S1: Anabolic Agents | OPSS entry |
| zilpaterol | imidazo(4,5,1-jk)(1)benzazepin-2(1H)-one, 4,5,6,7-tetrahydro-7-hydroxy-6-((1-methylethyl)amino)-, trans-(+-)-; imidazo(4,5,1-jk)(1)benzazepin-2(1H)-one, 4,5,6,7-tetrahydro-7-hydroxy-6-((1-methylethyl)amino)-, (6R,7R)-rel- | WADA S1: Anabolic Agents | OPSS entry |
| zipeprol | 1-methoxy-3[-4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol | DEA Controlled Substance List: Schedule I | OPSS entry |
| zolazepam | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one; flupyrazapon | DEA Controlled Substance List: Schedule III | OPSS entry |
| zolpidem | Ambien; Stilnoct; Ivadal; N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamid; Stilnox | DEA Controlled Substance List: Schedule IV | OPSS entry |
| zopiclone | Lunesta; Imovane; Zimovane | DEA Controlled Substance List: Schedule IV | OPSS entry |
| zuranolone | Zurzuvae | DEA Controlled Substance List: Schedule IV | OPSS entry |
Names, synonyms, reasons and references are OPSS’s own text for each entry, retrieved through the site’s search API on 2026-09-21; where an entry carries no reference link, the link goes to the OPSS search page.
How a banned ingredient reaches a bottle
A dietary supplement needs no approval before sale, and its maker, not FDA, is responsible for what goes in it. FDA finds a hidden drug after the fact, in four ways that show up as the “action” column above: import screening at the border (the “International Mail Shipments” rows), laboratory testing of products bought online, consumer and physician adverse-event reports through MedWatch, and inspections that end in a warning letter. The result is a public notification, sometimes a voluntary recall by the firm, and the product joins the database. FDA’s own caveat, printed on the database page, is that the list is a small fraction of what is sold.
The three product types that dominate the notifications share one mechanism. A “natural” sexual-enhancement capsule that works reliably usually works because it contains sildenafil or tadalafil, or an analogue nobody has tested in humans; a weight-loss tea that works usually contains sibutramine, an appetite suppressant withdrawn from the US market for cardiovascular risk, or phenolphthalein, a former laxative ingredient no longer approved for sale in the US; a muscle-building product that works usually contains an anabolic steroid or a SARM. The ingredient list on the label is the marketing; the drug is the product. Contamination with heavy metals or microbes is a manufacturing failure; a hidden drug is a design choice.
The ingredient directory captures a second route: substances sold openly as supplement ingredients that FDA says are not dietary ingredients at all. DMAA, for example, is category 3 in the directory (entry 2023/03), phenibut is category 3 (2023/03), tianeptine is category 2/3 (2023/03), and kratom is category 2/6 (2023/03); the category key is under the table above. These are not hidden; they are printed on the label of products still on sale, which is why the DoD keeps its own list for a population that is drug-tested.
How to check a product
- Search the product name in the FDA tainted-products table above (the full 1,406-row set is in the JSON file) and in FDA’s live database, which updates after this page’s fetch date.
- Read the ingredient panel against the ingredient directory and, if you are a service member, the DoD list. Search synonyms: the directory and OPSS both list them because labels use them.
- Check whether anyone tested the bottle. Our third-party tested database places every product we track on three tiers; a sport certification (NSF Certified for Sport, Informed Sport) is the only tier that screens each lot for banned substances, which is why the DoD and most leagues name those marks.
- Check the recall feed. Our supplement recalls page tracks FDA enforcement reports, including recalls for undeclared drug ingredients.
- Distrust the shape. A product promising sexual performance, rapid weight loss or muscle gain, sold through marketplaces or international mail, is the shape of 1,323 of the 1,406 notifications above.
Frequently asked questions
Is there an official FDA banned supplements list?
No. FDA does not maintain a single list of banned dietary supplements. What exists is (1) the FDA Health Fraud Product Database, which as of 2026-09-21 holds 1,406 product notifications naming a hidden or undeclared drug ingredient in a product sold as a supplement, from 2007 to 2026; (2) FDA's Dietary Supplement Ingredient Directory, 84 ingredients with FDA's statements, of which 61 are marked as not lawful dietary ingredients; and (3) for service members only, the Department of Defense prohibited-ingredients database maintained by Operation Supplement Safety (850 entries reachable through its search on 2026-09-21).
What supplements are banned by the military?
The Department of Defense prohibits service members from using any substance in its Operation Supplement Safety database as a dietary supplement ingredient, under DoD Instruction 6130.06, plus all controlled substances and drugs. The database is a search box with no download; we reached 850 ingredient entries through 3,000 queries on 2026-09-21, and because the crawl hit its budget before the queue emptied, that count is a lower bound. The list was last updated by OPSS on 26 May 2026. The most common reasons attached to entries are DEA Controlled Substance List: Schedule I (283), DEA Controlled Substance List: Schedule III (110), WADA S1: Anabolic Agents (110), DEA Controlled Substance List: Schedule IV (80), DEA Controlled Substance List: Schedule II (62), Prescription drug (62).
Is DMAA banned in supplements?
FDA's ingredient directory lists DMAA (1,3-DMAA; 1,3-Dimethylamylamine; 1,3-Dimethylpentylamine; 4-Methyl-2-hexanamine) under category 3: Ingredient is not a "dietary ingredient" under section 201(ff)(1) of the FD&C Act. FDA's position is that DMAA is not a lawful dietary ingredient and products containing it are adulterated; the directory entry links FDA's statement and enforcement actions (entry dated 2023/03). It is also on the DoD prohibited list.
What is the most common hidden ingredient in tainted supplements?
In the 1,406 hidden-ingredient notifications in the FDA database, the most frequent named ingredient is sildenafil (458 rows), followed by sibutramine (350) and tadalafil (261). By product type, 802 notifications involve sexual-enhancement drugs (sildenafil, tadalafil and their analogues), 428 involve weight-loss drugs (sibutramine, phenolphthalein, fluoxetine) and 93 involve anabolic steroids or SARMs; the category is our classification of the hidden ingredient, not an FDA field.
How do I report a supplement that made me sick?
Use FDA's MedWatch program (fda.gov/medwatch) for a product sold in the United States; keep the container and lot number. Service members and their providers can also report through the OPSS site. Reports feed the adverse-event data we summarise on our safety page and are how many of the notifications in the tables above started.
Related
- Third-party tested supplement database: 3 tiers, every brand
- Supplement recalls: the FDA enforcement feed
- How we score supplement safety (FAERS adverse events)
- The registry audit: how few supplements are certified
Sources
- US FDA. Health Fraud Product Database. https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database (fetched 2026-09-21; 2,202 rows, 1,406 with a hidden-ingredient subject). Former address: Tainted Products Marketed as Dietary Supplements.
- US FDA. Information on Select Dietary Supplement Ingredients and Other Substances (Dietary Supplement Ingredient Directory). https://www.fda.gov/food/dietary-supplements/information-select-dietary-supplement-ingredients-and-other-substances (content current as of 2026-05-01; fetched 2026-09-21; 84 entries).
- Operation Supplement Safety, Uniformed Services University. DoD Prohibited Dietary Supplement Ingredients. https://www.opss.org/dod-prohibited-dietary-supplement-ingredients (fetched 2026-09-21; 850 entries via 3,000 search queries; list dated 26 May 2026).
- Department of Defense. DoD Instruction 6130.06, Use of Dietary Supplements in the DoD. opss.org
- US FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. fda.gov/medwatch
- Verified Supplement Data. banned-supplements.json, the open-data version of the three lists (CC BY 4.0).